(54) Title: BROAD SPECTRUM VACCINE AGAINST NON-TYPHOIDAL SALMONELLA

FIG. 2

(57) Abstract: The present invention is drawn to attenuated *Salmonella* serovar strains *S.* Typhimurium and S. Enteritidis, conju-
gate vaccines derived from these attenuated strains of *S.* Typhimurium and *S.* Enteritidis, comprising an O polysaccharide cova-
lently linked to a flagellin protein, and methods for inducing an immune response in a subject comprising administering the atten-
uated strains and/or the conjugate vaccines of the invention.

Broad Spectrum Vaccine Against Non-typhoidal *Salmonella*

CROSS REFERENCE TO RELATED APPLICATIONS

This application claims the benefit of U.S. Appl. No. 61/145,124, filed
5   January 16, 2009. The content of the aforesaid application is relied upon and
incorporated by reference in its entirety.

STATEMENT OF FEDERALLY SPONSORED RESEARCH AND
DEVELOPMENT
10   This invention was made with government support under Grant No.
AI057168 awarded by the National Institutes of Health. The government has
certain rights in the invention.

FIELD OF THE INVENTION

The present invention generally relates at least to the fields of immunology,
15   molecular biology, infectious disease and medicine. In particular, the invention
relates to conjugate vaccines for non-typhoidal *Salmonella* infections, attenuated
non-typhoidal *Salmonella* strains, and to the use of those strains in heterologous
mucosal prime/parenteral boost immunization strategies which can be used to
markedly broaden the immune responses elicited over what can be currently
20   achieved with oral vaccine or conjugates alone.

BACKGROUND OF THE INVENTION

Bacteriology of the Complex Genus *Salmonella*. Only two species are
currently recognized within the genus *Salmonella*, *Salmonella enterica* and
Salmonella bongori, and only the former is important with respect to human
25   disease. There are six subspecies of *Salmonella enterica*, of which subspecies I, *S.
enterica subspecies enterica*, contains all the important pathogens that cause
human disease. *S. enterica subspecies enterica* is further sub-divided into more
than 2500 serovars (i.e., distinct serotypes) based on the presence of specific
somatic O antigens, capsular polysaccharide surface Vi antigen and flagellar H
30   antigens expressed by the organism. The antigenic serotyping scheme (previously
called the Kauffman-White scheme and more recently the White-Kauffmann-Le

Minor scheme) defines a serovar (i.e., serotype) by its O polysaccharide antigens (and also whether capsular polysaccharide Vi is expressed) and its H flagella antigens. The serogroup of a *Salmonella* is defined by its O antigens, while the serovar is defined by the full antigenic structure that includes all the flagellar

5   antigens and whether Vi polysaccharide is expressed. O antigens are part of the lipopolysaccharide (LPS) surface structure that is part of the outer membrane of the bacteria. The lipid A (endotoxin) portion of the LPS, is a glucosamine-based phospholipid that makes up the outer monolayer of the outer membrane of the bacteria. Attached to the lipid A is a core polysaccharide that is essentially

10   identical in all the important *Salmonella* serovars that cause human disease, particularly invasive disease. The more internal portion of the core polysaccharide is the "inner core", while the more external portion is the "outer core" (**FIG. 1**). Finally, the most external surface component that is attached to the outer core polysaccharide is a terminal O polysaccharide that consists of terminal O repeat

15   units linked one to another; this is what is exposed to the environment. The terminal O polysaccharide varies in structure depending on the sugars comprising the core unit and their linkages one to another. Many of the most important *Salmonella* serovars associated with human disease fall into serogroup B and serogroup D. The O repeat units of *Salmonella* serogroups B and D share a

20   common trisaccharide backbone that consists of repeats of mannose-rhamnose and galactose (Wyk P and Reeves P. *J. Bacteriol.* 1989; 171:5687-5693). This backbone is the structure for the common *Salmonella* epitope 12 that is found in serogroup B (4,[5],12) and Group D (9, 12). Attached to the backbone is another dideoxyhexose sugar that is alpha 1,3-linked to the mannose residue. If that

25   dideoxyhexose sugar is abequose, the resultant structure constitutes the immunodominant antigen "4" that defines O serogroup B. If the dideoxyhexose sugar that is alpha 1,3-linked to mannose is tyvelose, the resultant structure creates immunodominant antigen "9" that defines O serogroup D.

Some *Salmonella* can express two different antigenic forms of flagella, called Phase 1 and Phase 2. *Salmonella* Typhimurium has the antigenic scheme

30   1,4,(5),12:i:1,2. This indicates that it falls within O serogroup B (defined by antigen 4), expresses minor O antigens 1 and 12 and sometimes antigen 5 and

expresses Phase 1 flagella which manifest antigen H:i and Phase 2 flagella which manifest antigen H:1,2.

The serovars within *Salmonella enterica* subspecies *enterica* that can cause disease in humans can be divided into three broad clinico-pathological-epidemiologic categories that differ in clinical presentation, pathogenesis and epidemiology:

<u>Enteric Fever</u> - *Salmonella enterica* serovars Typhi (*S.* Typhi) and *Salmonella enterica* serovars Paratyphi A and B (*S.* Paratyphi A and *S.* Paratyphi B) cause, respectively, typhoid and paratyphoid fevers (collectively known as enteric fevers). Enteric fevers are febrile illnesses characterized by infection of the gut associated lymphoid tissue, liver, spleen, bone marrow and gall bladder and accompanied by a low level bacteremia (Levine MM. Typhoid Fever Vaccines. In: Plotkin SA, Orenstein WA, editors. Vaccines. Fourth ed. Philadelphia: Saunders; 2004. P. 1057-93). Sequencing of the *S.* Typhi and *S.* Paratyphi A genomes has revealed an impressive degree of homology (Parkhill J *et al.*, Nature 2001; 413:848-52; Deng W <u>et al.</u>, *J. Bacteriol.* 2003; 185:2330-7; McClelland M *et al.*, *Nat. Genet.* 2004; 36:1268-74).

<u>Septicemias and Metastatic Focal Infections</u> - A second (uncommon) set of *Salmonella* serovars, including *S.* Choleraesuis and *S.* Paratyphi C are characterized by their propensity to cause septicemia (*Salmonella* in the blood, accompanied by physiological derangements), multiple organ dysfunction and metastatic purulent infections such as osteomyelitis and focal abscesses (Saphra I, and Wasserman M. *Am. J. Med. Sci.* 1954; 228:525-33; Chen PL *et al.*, *J Microbiol. Immunol. Infect.* 2007; 40:240-7).

<u>Gastroenteritis and invasive disease caused by non-typhoidal Salmonella (NTS)</u> - The third set of *Salmonella*, commonly called non-typhoidal *Salmonella* (NTS) serovars, includes a large number of serovars that cause gastroenteritis (vomiting, fever and diarrhea). In healthy hosts NTS gastroenteritis is usually a self-limited clinical illness and is quite common. By contrast, in young infants, the elderly and immunocompromised hosts, NTS can cause severe and fatal disease in the U.S. (Vugia DJ *et al.*, *Clin. Infect. Dis.* 2004; 38 Suppl 3:S149-

S156; Kennedy M *et al.*, *Clin. Infect. Dis.* 2004; 38 Suppl 3:S142-S148; Voetsch AC *et al.*, *Clin. Infect. Dis.* 2004; 38 Suppl 3:S127-34.:S127-S134; Adak GK *et al.*, *Gut* 2002; 51:832-41) and abroad (Adak GK *et al.*, *Gut* 2002; 51:832-41; Graham SM *et al.*, *Pediatr. Infect. Dis. J.* 2000; 19:1189-96; Walsh AL *et al.*,

5   *Pediatr. Infect. Dis. J.* 2000; 19:312-8; Berkley JA *et al.*, *N. Engl. J. Med.* 2005; 352:39-47; Kariuki S *et al.*, *BMC. Microbiol.* 2006; 6:101; Kariuki S *et al.*, *J. Med. Microbiol.* 2006; 55:585-91; Hill PC *et al.*, *BMC. Infect. Dis.* 2007; 7:2; Ikumapayi UN *et al.*, *J. Med. Microbiol.* 2007; 56:1479-84; Levy H *et al.*, *J. Clin. Microbiol.* 2008; 46:1861-6). In sub-Saharan Africa, invasive disease associated with NTS

10   often occurs without accompanying gastroenteritis. While non-typhoidal *Salmonella* (NTS) has long been known to be a cause of gastroenteritis, as noted by some of the above-cited documents, it is becoming increasingly recognized both in the U.S. and globally, that multiple antibiotic-resistant strains are also emerging as important causes of invasive bacteremia and focal infections, resulting in

15   hospitalizations and deaths.

       Predominant NTS serovars and epidemiologic insights - In the U.S. and Europe, a relatively small number of *Salmonella* account for the vast majority of cases of gastroenteritis and two serovars, *S.* Typhimurium and *S.* Enteritidis, account for 45-60% of all cases (Voetsch AC *et al.*, *Clin. Infect. Dis.* 2004; 38

20   Suppl 3:S127-34.:S127-S134; Adak GK *et al.*, *Gut* 2002; 51:832-41). In certain age groups (e.g., infants), the incidence is high (estimated by the US Centers for Disease Control to be approximately 120 cases per 100,000 infants) (Vugia DJ *et al.*, *Clin. Infect. Dis.* 2004; 38 Suppl 3:S149-56.:S149-S156). In young infants (<3 months age), the elderly and immunocompromised hosts (e.g., on chemotherapy

25   for cancer or autoimmune diseases), NTS often leads to severe clinical disease, meningitis and death (Vugia DJ *et al.*, *Clin. Infect. Dis.* 2004; 38 Suppl 3:S149-S156; Kennedy M *et al.*, *Clin. Infect. Dis.* 2004; 38 Suppl 3:S142-S148). Among infants and elderly (>60 years), 25% and 47% of all reported cases, respectively, end up hospitalized (Kennedy M *et al.*, *Clin. Infect. Dis.* 2004; 38 Suppl 3:S142-

30   S148). Increasingly, NTS strains associated with invasive disease are being identified that are difficult to treat because of their resistance to multiple, clinically relevant, antibiotics (Varma JK *et al.*, *J. Infect. Dis.* 2005; 191:554-61). Such

multi-resistant strains make invasive NTS disease an important infectious disease problem (*Id.*). In the USA, the Foodborne Diseases Active Surveillance Network (FoodNet), a component of the Emerging Infections Program of the Centers for Disease Control, coordinates active surveillance for foodborne disease and

5   undertakes studies to elucidate the epidemiology of foodborne diseases and to evaluate interventions to diminish disease burden. Notably, whereas the incidence of disease caused by other important enteric pathogens such as *Campylobacter jejuni* and enterohemorrhagic *Escherichia coli* has been halved consequent to interventions initiated by FoodNet, the incidence of NTS has remained the same.

10   The failure of interventions that are effective against other bacterial enteropathogens to diminish the NTS disease burden makes vaccination against NTS an attractive option. In Africa, invasive NTS is a major killer of infants and toddlers (ages 3-11) and >80% of the cases are caused by *S.* Typhimurium and *S.* Enteritidis.

15   **NTS and biodefense** - The largest bioterror incident ever in the USA involved *S.* Typhimurium (Torok TJ *et al.*, *JAMA* 1997; 278:389-95). Members of a religious commune deliberately contaminated salad bars in restaurants, leading to a protracted outbreak of gastrointestinal illness that resulted in 751 cases (*Id.*). Because NTS outbreaks in the USA are not uncommon (Braden CR. *Clin. Infect.*

20   *Dis.* 2006; 43:512-7; Chittick P *et al. J. Food Prot.* 2006;69:1150-3), detection of a deliberate release is not easy and requires enhanced surveillance.

             Heterologous prime/boost immunization regimens. When critical antigens in different forms or via different routes are used to prime and boost, the breadth and magnitude of the immune response is increased. Heterologous

25   prime/boost is a highly flexible strategy to enhance immunogenicity. The initial observations in mice involved enhancing immune responses to protein antigens (Vindurampulle CJ *et al.*, *Vaccine* 2004; 22:3744-50). Mucosal immunization with *S.* Typhi expressing fragment C of tetanus toxin primed mice to develop enhanced serum tetanus toxin neutralizing antibody titers when mice were subsequently

30   inoculated parenterally with a single dose of tetanus toxoid (*Id.*). Similarly, non-human primates immunized mucosally (nasally) with *S.* Typhi expressing full

length Protective Antigen (PA) of *Bacillus anthracis* mounted anamnestic serum antibody responses when immunized subsequently with a single dose of parenteral vaccine containing PA. Unconjugated pneumococcal, meningococcal and *S.* Typhi Vi polysaccharides that exist as licensed vaccines for adults and older children are not immunogenic in infants, and even in adults immune responses cannot be boosted and are relatively short-lived compared to protein antigens (Keitel WA *et al., Vaccine* 1994; 12:195-9). A clinical trial is currently underway addressing whether oral immunization of volunteers with CVD 909 (Wang JY *et al., Infect. Immun.* 2000:4647-52; Tacket CD *et al., J. Infect. Dis.* 2004; 190:565-70), an attenuated *S.* Typhi vaccine strain that constitutively expresses Vi capsular polysaccharide can prime vaccines to mount enhance serum Vi antibody responses when subsequently immunized with parenteral Vi polysaccharide. We propose that mucosal administration with live attenuated NTS vaccines primes the immune system of animals to mount enhanced, broadened immune responses when they are subsequently given the homologous O:H glycoconjugate (i.e., OPS linked to Phase 1 flagellar protein) parenterally.

The present invention relates to appropriately engineered attenuated strains of *Salmonella enterica* serovars Typhimurium and Enteritidis and their use in vaccinating against these NTS serovars by: 1) allowing safer, high yield preparation of purified O polysaccharide (OPS) and flagella protein for making conjugate vaccines, and 2) by their use in a heterologous mucosal prime/parenteral boost immunization strategy in which subjects given the attenuated strains of *S.* Typhimurium and *S.* Enteritidis orally are subsequently boosted parenterally with conjugate vaccine comprising *Salmonella* Group B or D OPS covalently linked, respectively, to phase 1 flagella protein of *S.* Typhimurium and *S.* Enteritidis. The invention will markedly broaden the immune responses elicited and enhance antibodies and cell mediated immunity (CMI) stimulated by the live vaccine to synergize with the serum IgG anti-OPS bactericidal antibodies and anti-flagella antibodies stimulated by the parenteral conjugate vaccine. Since *S.* Typhimurium and *S.* Enteritidis are the most common NTS serovars associated with invasive and severe NTS clinical disease in the USA, and globally, the invention encompasses a rational, broad spectrum vaccine against NTS. It is contemplated that the bivalent

vaccine will also cross protect against other Group B and D serovars. Addition of a group C1 or C2 conjugate is further contemplated. As such, coverage will be provided against virtually all NTS associated with invasive and severe NTS disease in the U.S. and worldwide.

5   SUMMARY OF THE INVENTION

According to non-limiting example embodiments, in one aspect, the present invention is directed to methods that include the production of well tolerated and immunogenic vaccine strains of *Salmonella* Typhimurium and *Salmonella*

10   Enteritidis.

In another aspect, the invention is directed to a *Salmonella* serovar strain, wherein the strain has at least one attenuating mutation selected from group consisting of an attenuating mutation in the *guaBA* locus, the *guaB* gene, the *guaA* gene, the *clpP* gene, the *clpX* gene and the *clpPX* locus and said *Salmonella*

15   serovar is selected from the group consisting of *Salmonella* Typhimurium (a serovar within serogroup B) and *Salmonella* Enteritidis (a serovar within serogroup D).

In another aspect, the present invention is directed to conjugate vaccines. In particular, the present invention encompasses a *Salmonella enterica* serovar

20   conjugate vaccine comprising an O polysaccharide (OPS) conjugated to a flagellin protein or a fragment or a derivative thereof, such as a Phase 1 major flagella subunit protein (flagellin, the gene product encoded by *fliC*) from epidemiologically relevant serovars such as *S.* Typhimurium and *S.* Enteritidis.

In another aspect, the invention is directed to methods of inducing an

25   immune response, comprising administering to a subject in need thereof an effective amount of a *Salmonella enterica* serovar conjugate vaccine comprising an O polysaccharide of serogroup B conjugated to Phase 1 (H:i) or Phase 2 (H:1,2) flagella protein of *S.* Typhimurium or O polysaccharide of group D conjugated to Phase 1 flagella of *S.* Enteritidis (H:g,m).

30   In some embodiments, the invention is directed to methods of inducing an immune response, comprising administering to a subject in need thereof a vaccine

comprising an effective amount of genetically modified attenuated *Salmonella enterica* serovar selected from the group consisting of *S.* Typhimurium and *S.* Enteritidis.

5   In another aspect, the invention is directed to methods for preventing or attenuating an infection caused by *Salmonella*, comprising administering to a subject in need thereof a first vaccine comprising an effective amount of genetically modified attenuated *Salmonella enterica* serovar and a second vaccine comprising an effective amount of a conjugate comprising a homologous O polysaccharide (OPS) and a flagellin protein, such as a Phase 1 flagella protein or a

10   fragment or a derivative thereof.

In another aspect, the invention is directed to a pharmaceutical formulation comprising one or more of the attenuated *Salmonella* strains of the present invention.   In some embodiments of the invention, the formulations are oral pharmaceutical formulations.

15   In another aspect, attenuated *Salmonella* Typhimurium and *Salmonella* Enteritidis vaccine strains can be genetically modified to hyper-express Phase 1 flagella with the practical goal of enhancing yields of purified flagella protein which can be used as a carrier protein in conjugate vaccines.

BRIEF DESCRIPTION OF THE FIGURES

20   FIG. 1. Structure of the cell wall from a typical Gram-negative bacterium.

FIG. 2. Deletion of chromosomal *guaBA* from attenuated *Salmonella enterica* serovar Typhimurium vaccine strain CVD 1925 using lambda Red-mediated mutagenesis.

FIG. 3. Deletion of chromosomal *clpP* from attenuated *Salmonella enterica*

25   serovar Typhimurium vaccine strain CVD 1925 using lambda Red-mediated mutagenesis.

FIG.4. Deletion of the chromosomal *fljBA* locus from attenuated *Salmonella enterica* serovar Typhimurium vaccine strain CVD 1925 using lambda Red-mediated mutagenesis.

FIG. 5. Deletion of chromosomal *fliD* from attenuated *Salmonella enterica* serovar Typhimurium vaccine strain CVD 1925 using lambda Red-mediated mutagenesis.

FIG. 6. Expression of flagella in the supernatants of attenuated NTS strains

derived from *Salmonella enterica* serovar Typhimurium I77 and *Salmonella enterica* serovar Enteritidis R11.

FIG. 7. Purification of *Salmonella* Enteritidis Flagella. *Salmonella* Flagella were isolated as described utilizing mechanical shearing followed by differential centrifugation. Protein samples were analyzed by SDS-PAGE followed by staining with Coomasie dye (A), or by transfer to a PVDF membrane followed by western blot analysis with a monoclonal antibody specific for bacterial flagellin (B). Lane 1: *Salmonella* cells; lane 2: 10KxG centrifugation resuspended *Salmonella* cell pellet following mechanical shearing; lane 3: 10KxG centrifugation sheared cell supernatant; lane 4: 100,000KxG precipitated flagella material.

FIG. 8. Purification of *Salmonella* Lipopolysaccharide. (A) Emerald Green stained SDS-PAGE pattern of *S.* Enteritidis LPS. Lane: 1, 37.5ug; 2, 70ug. (B) Size exclusion gel filtration profile of *S.* Enteritidis OPS through a Superdex 70 sepharose column in PBS. High molecular weight OPS fractions are designated 16-22. Polysaccharide concentrations were assessed by resorcinol assay, using the homologous LPS as a standard.

FIG. 9. Conjugation of *Salmonella* Outer Membrane Polysaccharide to Flagellin monomers. 4-20% SDS-Gel followed by Coomasie (A) or Emerald Green (B) staining. Lane: 1, 10ug LPS; 2, 6ug HMW-OPS; 3, 6ug de-polymerized flagella; 4, 6ug protein as conjugate to HMW-OPS; 5, 3ug protein as conjugate to HMW-OPS. (C) Western Blot analysis for flagellin. Lane: 1, .4ug depolymerized flagella; 2, .4ug protein as conjugate to HMW-OPS.

FIG. 10. Purification of Flagellin-OPS Conjugates. Gel filtration pattern of Flagella-HMW-OPS conjugates through a Superdex 700 size exclusion column. (A) Fractions were analyzed by SDS-PAGE with staining with Coomasie dye for protein. (B) Polysaccharide content in each fraction.

DETAILED DESCRIPTION OF THE INVENTION

Conjugate vaccines

In one aspect, the present invention is directed to conjugate vaccines for *Salmonella*. In particular, the present invention encompasses *Salmonella* conjugate

5   vaccines comprising an O-polysaccharide (OPS) conjugated to a flagellin protein. A conjugate vaccine comprising a flagellin protein comprises any known flagellin protein (see, for example, International Application PCT/US2004/034910 and US 60/512,878, which are incorporated by reference in their entirety). In particular aspects of the invention, a flagellin protein is any known flagellin protein of *S.*

10   Typhimurium or *S.* Enteritidis. In some embodiments of the invention, the flagellin protein is a phase 1 flagella protein (FliC).

As used herein, the term "phase 1 flagella" is intended to encompass: 1] flagella expressed from biphasic serovars such as *S.* Typhimurium, where both a phase 1 (FliC) and an additional phase 2 flagella (FljB) are expressed, and 2]

15   flagella expressed by monophasic *Salmonella* serovars such as *S.* Enteritidis, which express only one type of flagella (FliC).

An OPS-flagella protein conjugate vaccine in which the OPS derives from epidemiologically relevant O serogroups such as serogroup B (which includes serovar *S.* Typhimurium) or serogroup D (which includes serovar *S.* Enteritidis).

20   The OPS and flagellin protein of the conjugated vaccine may be identical to a molecule which is characteristic of a *Salmonella* serovar, or they may be derivatives or fragments of such molecules. Preferably, the flagellin protein is from the same *Salmonella* serovar as the OPS. In some embodiments, the *Salmonella* serovar is selected from the group consisting of Group B and Group D

25   serovars. In some embodiments, the OPS and flagellin protein are characteristic of *S.* Typhimurium (Group B). In some embodiments, the OPS and flagella protein are characteristic of *S.* Enteritidis (Group D). In some embodiments of the present invention, the conjugate vaccines provide more immunogenicity and protection than those OPS conjugated to standard carrier proteins (e.g., Corynebacterium

30   diphtheria CRM).

In some embodiments, the conjugate vaccine comprises an OPS of serogroup B *Salmonella* (which includes serovar *S*. Typhimurium) covalently linked to the Phase 1 H:i flagella of serovar *S*. Typhimurium. This conjugate vaccine would also protect against an epidemiologically important variant of *S*. Typhimurium, serovar I 4,[5],12:i:-. clinically relevant level of cross protection might also be conferred against other epidemiologically important serovars within serogroup B such as *Salmonella* Heidelberg (antigenic formula 1,4,5,12:r:1,2), which is important in the USA, and *Salmonella* Stanleyville (antigenic formula 1,4,5,12:z4,z23:1,2), which is important in sub-Saharan Africa. The cross protection would be based on antibodies directed against shared O antigen 4, the immunodominant O antigen that defines serogroup B *Salmonella*.

In some embodiments, the conjugate vaccine for *S*. Enteritidis infections comprises an OPS of serogroup D (which includes serovar *S*. Enteritidis) covalently linked to the Phase 1 H:g,m flagella of serovar *S*. Enteritidis. This conjugate would be expected to provide cross protection against *Salmonella* Dublin (antigenic formula 1,9,12:g,p:-[Vi]), which is an epidemiologically important cause of invasive NTS disease in the USA and in some parts of sub-Saharan Africa (Levy H *et al*. *J Clin Microbiol* 2008; 46: 1861-1866; Tennant *et al* PLoS-NTD 2010; in press).

In some embodiments, the conjugate vaccines made from *S*. Typhimurium or *S*. Enteritidis are able to confer immunity against other *Salmonella* serovars. In some embodiments, immunity is conferred against *S*. Heidelberg (Group B, H:r) and S. Panama (Group D, H:l,v) serovars, which share O group but not Phase 1 H serotype antigens with *S*. Typhimurium and *S*. Enteritidis.

In some embodiments, the OPS and Phase 1 flagella protein are isolated from an attenuated *S*. Typhimurium (Group B) or *S*. Enteritidis (Group D) strain. In some embodiments, the OPS and Phase 1 flagella proteins are isolated from the genetically modified attenuated strains described herein. In some embodiments, the *S*. Typhimurium (Group B) or *S*. Enteritidis (Group D) has at least one attenuating mutation selected from group consisting of an attenuating mutation in the *guaBA* locus, the *guaB* gene, the *guaA* gene, the *clpP* gene, the *clpX* gene, and

the *clpPX* locus. Combinations of attenuating mutations are further contemplated in accordance with the invention.

Salmonella serovars harboring a mutation in the *clpP* gene (that encodes a protease) are hyper-flagellated yet do not exhibit diminished bacterial cell growth at 30° or 37° C. Such serovars include, for example, *S.* Typhimurium (Tomoyasu T *et al.*, *J. Bacteriol.* 2002; 184:645-53). Such strains could greatly enhance the yields of flagella protein during large-scale manufacture, and the use of such strains to produce conjugate vaccines is encompassed by the present invention.

In one embodiment, the immunogenicity of the conjugate vaccine is greater than the immunogenicity of at least one carrier alone. Methods of measuring immunogenicity are well known to those in the art and primarily include measurement of serum antibody including measurement of amount, avidity, and isotype distribution at various times after injection of the conjugate vaccine. Greater immunogenicity may be reflected by a higher titer and/or increased life span of the antibodies. Immunogenicity may also be measured by the ability to induce protection to challenge with noxious substances or virulent organisms. Immunogenicity may also be measured by the ability to immunize neonatal and/or immune deficient mice. Immunogenicity may be measured in the patient population to be treated or in a population that mimics the immune response of the patient population.

In some embodiments of the present invention, the OPS and their homologous flagellin, e.g, Phase 1 flagella protein, in accordance with the invention can include functional groups or, alternatively, can be chemically manipulated to bear functional groups. The presence of functional groups may facilitate covalent conjugation. Such functional groups include, but are not limited to, amino groups, carboxyl groups, aldehydes, hydrazides, epoxides, and thiols.

In one embodiment, the invention provides a conjugate vaccine capable of inducing an immune response, the vaccine comprising (a) an OPS of *S.* Typhimurium conjugated to (b) Phase 1 flagella protein of *S.* Typhimurium or a fragment or derivative thereof.

In another embodiment, the invention provides a conjugate vaccine capable of preventing or attenuating an infection caused by *Salmonella* Enteritidis, the vaccine comprising (a) an OPS of *S.* Enteritidis conjugated to (b) Phase 1 flagella protein of *S.* Enteritidis or a fragment or derivative thereof.

In some embodiments, fragments or derivatives of the Phase 1 flagella for use in the conjugate vaccine include any internal antigenic portion(s) of the Phase 1 flagella protein.

In some embodiments, the OPS is one which, when introduced into a mammal (either animal or human) elicits antibodies which are capable of reacting with the *Salmonella* from which the OPS is derived.

Examples of fragments or derivatives of the Phase 1 flagella protein include fragments of the natural protein, including internal sequence fragments of the protein that retain their ability to elicit protective antibodies against the *Salmonella* from which it is derived. The derivatives are also intended to include variants of the natural protein (such as proteins having changes in amino acid sequence but that retain the ability to elicit an immunogenic, biological, or antigenic property as exhibited by the natural molecule), for example, the variants of the Phase 1 flagella protein with an altered flanking sequence.

By derivative is further meant an amino acid sequence that is not identical to the wild type amino acid sequence, but rather contains at least one or more amino acid changes (deletion, substitutions, inversion, insertions, etc.) that do not essentially affect the immunogenicity or protective antibody responses induced by the modified protein as compared to a similar activity of the wild type amino acid sequence, when used for the desired purpose. In some embodiments, a derivative amino acid sequence contains at least 85-99% homology at the amino acid level to the specific amino acid sequence. In further embodiments, the derivative has at least 90% homology at the amino acid level, while in other embodiments, the derivative has at least 95% homology.

The Phase 1 flagella protein that is conjugated to the polysaccharide in the vaccine of the invention may be a peptide encoding the native amino acid sequence or it may be a derivative or fragment of the native amino acid sequence.

In some embodiments, Phase 1 flagella protein from other serovars of *Salmonella* may also be prepared and used in a similar manner as a slight variability in the sequence of the protein might not alter the biological properties and their functional ability to elicit protective antibodies against other serovars. In some embodiments, a conjugate vaccine comprising a Phase 1 flagella protein from a particular group B serovar can provide protection against other group B serovars, for example, in addition to protection against the group B serovar from which it was derived.

The peptides used in the invention, whether encoding a native protein or a derivative thereof, are conjugated to an OPS moiety by any means that retains the ability of these proteins to induce protective antibodies against *Salmonella*.

Heterogeneity in the vaccine may be provided by mixing specific conjugated species. For example, the vaccine preparation may contain one or more copies of one of the peptide forms conjugated to the carbohydrate, or the vaccine preparation may be prepared to contain more than one form of the above derivatives and/or the native sequence, each conjugated to a polysaccharide used therein.

A multivalent vaccine may also be prepared by mixing the OPS and Phase 1 flagella protein conjugates with other proteins, such as other *Salmonella* antigens, antigens against other organisms, diphtheria toxin or tetanus toxin, and/or other polysaccharides, using techniques known in the art. In some embodiments, the invention is directed to a multivalent vaccine comprising a mixture of conjugates derived from various *Salmonella* serovars, each conjugate comprising an OPS and Phase 1 flagella protein characteristic of the serovar.

In one embodiment, the *S.* Enteritidis or *S.* Typhimurium conjugate vaccines of the invention are combined with conjugate vaccines from *Salmonella* group C1 and/or group C2 serovars. In some embodiments, group C1 or C2 serovar conjugate vaccines can likewise comprise OPS and Phase 1 flagella proteins characteristic of the C1 or C2 serovars, and prepared in accordance with the invention.

As used herein, a polysaccharide or protein is "characteristic" of bacteria if it is substantially similar or identical in structure or sequence to a molecule

14

naturally associated with the bacteria. The term is intended to include both molecules which are specific to the organism, as well as molecules which, though present on other organisms, are involved in the virulence or antigenicity of the bacteria in a human or animal host.

5   In some embodiments, the flagellin protein is isolated from genetically modified *Salmonella*. In some embodiments, the genetically modified *Salmonella* include *S*. Typhimurium or *S*. Enteritidis that harbor an attenuating mutation in *clpP* (that encodes a protease) that results in variants that are hyper-flagellated yet do not exhibit diminished bacterial cell growth at 30° or 37°C (Tomoyasu T *et al.*,

10   *J. Bacteriol.* 2002; 184:645-53). In some embodiments, use of such mutants greatly enhances the yields of flagella protein during large-scale manufacture. In some embodiments, the *S*. Typhimurium or *S*. Enteritidis cells are engineered to overexpress FliC Phase 1 flagella monomers (FliC). In some embodiments, *fliD* will also be deleted, leading to secretions of non-polymerized extracellular FliC

15   monomers. In some embodiments, the *fljB* gene of *S*. Typhimurium is also deleted, which encodes an alternate phase 2 flagellin not required for the conjugate vaccine.

         In some embodiments, the *S*. Typhimurium or *S*. Enteritidis cells are modified to harbor multiple gene copies to overexpress Phase 1 flagella protein. In some embodiments, the Phase 1 flagella protein is recombinantly produced, for

20   example, in *E. coli*.

Methods of Making the Conjugate Vaccine

         Preparation of purified protein from flagella structures on bacterial cells, or secreted flagellin protein, including but not limited to homologous and

25   heterologous *Salmonella* strains, expressing the desired flagellin protein, or bacterial expression system such as *E. coli*, for use in conjugation can be accomplished through several methodologies, including but not limited to, mechanical shearing, removal at low pH, heating or purification from bacterial supernatants. Mechanical shearing has been shown to be effective in preparation of

30   flagellin protein suitable for conjugation to OPS.

         Purification of OPS can be accomplished by methods including by not limited to mild acid hydrolysis removal of lipid A from LPS, as this has been

shown to preserve the O-acetyl groups that are important for immunogenicity. Other embodiments may include hydrazine as an agent for OPS preparation. Preparation of LPS can be accomplished by methods including but not limited to those of Darveau, R.P., and Hancock, R.E.W. 1983. *J. Bacteriol.*, 155(2):831-838,

5   or Westphal, O. and Jann, K. 1965. Methods in Carbohydrate Chemistry. 5:83-91 as are incorporated by reference herein. As is shown in **FIGS. 8 and 9**, LPS was purified by a modification of the methods of Darveau and Hancock, followed by mild acid hydrolysis to remove lipid A and liberate free Core/KDO linked OPS. Conjugation of OPS of *S.* Typhimurium or *S.* Enteritidis and a flagellin protein of

10   the same serovar can be carried out by methods as described in, for example, US Patent Application Publication No. 20090028889. Techniques to conjugate OPS and the Phase 1 flagella protein include, in part, coupling through available functional groups (such as amino, carboxyl, thio and aldehyde groups). See, e.g., Hermanson, Bioconjugate Techniques (Academic Press; 1992); Aslam and Dent,

15   eds. Bioconjugation: Protein coupling Techniques for the Biomedical Sciences (MacMillan: 1998); S. S. Wong, *Chemistry of Protein Conjugate and Crosslinking CRC Press* (1991), and Brenkeley *et al.*, Brief Survey of Methods for Preparing Protein Conjugates With Dyes, Haptens and Cross-Linking Agents, *Bioconjugate Chemistry* 3 #1 (Jan. 1992); Jacob, C. O, *et al.*, *Eur. J. Immunol.* 16:1057-1062

20   (1986); Parker, J. M. R. *et al.*, In: *Modern Approaches to Vaccines*, Chanock, R. M. *et al.*, eds, pp. 133-138, Cold Spring Harbor Laboratory, Cold Spring Harbor, N.Y. (1983); Zurawski, V. R, *et al.*, *J. Immunol.* 121:122-129 (1978); Klipstein, F. A, *et al.*, *Infect. Immun.* 37:550-557 (1982); Bessler, W. G, *Immunobiol.* 170:239-244 (1985); Posnett, D. N, *et al.*, *J. Biol. Chem.* 263:1719-1725 (1988); Ghose, A.

25   C, *et al.*, *Molec. Immunol.* 25:223-230 (1988); all of which disclosures are incorporated herein by reference). An example of a conjugate vaccine was developed against *Haemophilus influenzae* (Anderson, P, Infec. and *Immunology* 39:223-238 (1983); Chu, C, *et al.*, *Infect. Immun.* 40:245-256 (1983); Lepow, M, *Pediat. Infect. Dis. J.* 6:804-807 (1987), which disclosures are incorporated herein

30   by reference), and this model may be employed in constructing the novel vaccines of the present invention. Additional methods for producing such a conjugate vaccine are disclosed by European Patent Publication 245,045; U.S. Pat. Nos.

4,673,574 and 4,761,283; U.S. Pat. No. 4,789,735; European Patent Publication No. 206,852; U.S. Pat. No. 4,619,828; U.S. Pat. No. 4,284,537; U.S. Pat. No. 5,192,540; U.S. Pat. No. 5,370,872; U.S. Pat. No. 5,302,386; and U.S. Pat. No. 5,576,002 all of which disclosures are incorporated herein by reference.

5   For example, in the case of carbohydrate or lipid conjugation, functional amino and sulfhydryl groups may be incorporated therein by conventional chemistry. For instance, primary amino groups may be incorporated by reaction with ethylenediamine in the presence of sodium cyanoborohydride and sulfhydryls may be introduced by reaction of cysteamin dihydrochloride followed by reduction

10   with a standard disulfide reducing agent.

Heterobifunctional crosslinkers, such as, for example, sulfosuccinimidyl (4-iodoacetyl) aminobenzoate, which link the epsilon amino group on the D-lysine residues of copolymers of D-lysine and D-glutamate to a sulfhydryl side chain from an amino terminal cysteine residue on the peptide to be coupled, may be used

15   to increase the ratio of OPS to a flagellin protein and/or a flagellin protein to OPS in the conjugate.

Flagellin protein may contain amino acid side chains such as amino, carbonyl, hydroxyl, or sulfhydryl groups or aromatic rings that can serve as sites for conjugation. Residues that have such functional groups may be added to either

20   OPS or to a flagellin protein. Such residues may be incorporated by solid phase synthesis techniques or recombinant techniques, both of which are well known in the art.

OPS and a flagellin protein may be chemically conjugated using conventional crosslinking agents such as carbodiimides. Examples of

25   carbodiimides are 1-cyclohexyl-3-(2-morpholinyl-(4-ethyl) carbodiimide (CMC), 1-ethyl-3-(3-dimethyaminopropyl) carbodiimide (EDC), and 1-ethyl-3-(4-azonia-44-dimethylpentyl) carbodiimide.

Examples of other suitable crosslinking agents are cyanogen bromide, glutaraldehyde and succinic anhydride. In general, any of a number of

30   homobifunctional agents including a homobifunctional aldehyde, a homobifunctional epoxide, a homobifunctional imidoester, a homobifunctional N-hydroxysuccinimide ester, a homobifunctional maleimide, a homobifunctional

alkyl halide, a homobifunctional pyridyl disulfide, a homobifunctional aryl halide, a homobifunctional hydrazide, a homobifunctional diazonium derivative or a homobifunctional photoreactive compound may be used. Also included are heterobifunctional compounds, for example, compounds having an amine-reactive

5   and a sulfhydryl-reactive group, compounds with an amine-reactive and a photoreactive group, and compounds with a carbonyl-reactive and a sulfhydryl-reactive group.

Specific examples of homobifunctional crosslinking agents include the bifunctional N-hydroxysuccinimide esters dithiobis (succinimidylpropionate),

10   disuccinimidyl suberate, and disuccinimidyl tartarate; the bifunctional imidoesters dimethyl adipimidate, dimethyl pimelimidate, and dimethyl suberimidate; the bifunctional sulfhydryl-reactive crosslinkers 1,4-di-[3'-(2'-pyridyldithio) propion-amido]butane, bismaleimidohexane, and bis-N-maleimido-1,8-octane; the bifunctional aryl halides 1,5-difluoro-2,4-dinitrobenzene and 4,4'-difluoro-3,3'-

15   dinitrophenylsulfone; bifunctional photoreactive agents such as bis-[b-(4-azidosalicylamide)ethyl]disulfide; the bifunctional aldehydes formaldehyde, malondialdehyde, succinaldehyde, glutaraldehyde, and adiphaldehyde; a bifunctional epoxied such as 1,4-butaneodiol diglycidyl ether; the bifunctional hydrazides adipic acid dihydrazide, carbohydrazide, and succinic acid dihydrazide;

20   the bifunctional diazoniums o-tolidine, diazotized and bis-diazotized benzidine; the bifunctional alkylhalides N1N'-ethylene-bis(iodoacetamide), N1N'-hexamethylene-bis(iodoacetamide), N1N'-undecamethylene-bis(iodoacetamide), as well as benzylhalides and halomustards, such as ala'-diiodo-p-xylene sulfonic acid and tri(2-chloroethyl)amine, respectively.

25   Examples of other common heterobifunctional crosslinking agents that may be used include, but are not limited to, SMCC (succinimidyl-4-(N-maleimidomethyl)cyclohexane-1-carboxylate), MBS (m-maleimidobenzoyl-N-hydroxysuccinimide ester), SIAB (N-succinimidyl(4-iodacteyl) aminobenzoate), SMPB (succinimidyl-4-(p-maleimidophenyl)butyrate), GMBS (N-(-

30   maleimidobutyryloxy)succinimide ester), MPHB (4-(4-N-maleimidopohenyl) butyric acid hydrazide), M2C2H (4-(N-maleimidomethyl)cyclohexane-1-carboxyl-hydrazide), SMPT (succinimidyloxycarbonyl-a-methyl-a-(2-pyridyldithio)toluene),

and SPDP (N-succinimidyl 3-(2-pyridyldithio) propionate). For example, crosslinking may be accomplished by coupling a carbonyl group to an amine group or to a hydrazide group by reductive amination.

In another aspect of the invention, OPS and a flagellin protein are conjugated through polymers, such as PEG, poly-D-lysine, polyvinyl alcohol, polyvinylpyrollidone, immunoglobulins, and copolymers of D-lysine and D-glutamic acid. Conjugation of OPS to a flagellin protein may be achieved in any number of ways, including involving one or more crosslinking agents and functional groups on the OPS and/or a flagellin protein. The polymer may be derivatized to contain functional groups if it does not already possess appropriate functional groups.

In some embodiments, 1-cyano-4-dimethylaminopyridinium tetrafluoroborate (CDAP) conjugation chemistry is used to achieve efficient synthesis of group-specific OPS-FliC conjugates (see e.g. Lees A. *et al.* 1996. *Vaccine.* 14(3):190-198, and Shafer DE *et al. Vaccine.* 2000. 18(13):1273-81 as is incorporated by reference herein). As shown in **FIG. 9**, activation and derivitization of OPS with CDAP chemistry, followed by direct coupling to flagellin protein has been demonstrated to be effective as a method of conjugation.

In some embodiments, the OPS or Phase 1 flagella protein is conjugated to a linker prior to conjugation. In some embodiments, the linker is adipic acid dihydrazide (ADH). The present invention contemplates the use of any linker capable of conjugating OPS to a Phase 1 flagella protein. In some embodiments, the presence of a linker promotes optimum immunogenicity of the conjugate and more efficient coupling. In some embodiments, the linkers separate the two antigenic components by chains whose length and flexibility can be adjusted as desired. Between the bifunctional sites, the chains can contain a variety of structural features, including heteroatoms and cleavage sites. In some embodiments, linkers also permit corresponding increases in translational and rotational characteristics of the antigens, increasing access of the binding sites to soluble antibodies. Besides ADH, suitable linkers include, for example, heterodifunctional linkers such as ε-aminohexanoic acid, chlorohexanol dimethyl acetal, D-glucuronolactone and p-nitrophenyl amine. Coupling reagents

contemplated for use in the present invention include hydroxysuccinimides and carbodiimides. Many other linkers and coupling reagents known to those of ordinary skill in the art are also suitable for use in the invention. Such compounds are discussed in detail by Dick *et al.*, Conjugate Vaccines, J. M. Cruse and R. E. Lewis, Jr., eds., Karger, New York, pp. 48-114, hereby incorporated by reference.

In some embodiments, ADH is used as the linker. In some embodiments, the molar ratio of ADH to OPS in the reaction mixture is typically between about 10:1 and about 250:1. In some embodiments, a molar excess of ADH is used to ensure more efficient coupling and to limit OPS-OPS coupling. In some embodiments, the molar ratio is between about 50:1 and about 150:1. In other embodiments, the molar ratio is about 100:1. Similar ratios of AH-OPS to the Phase I flagella protein in the reaction mixture are also contemplated. In some embodiments, one ADH per OPS is present in the AH-OPS conjugate.

Other linkers are available and can be used to link two aldehyde moieties, two carboxylic acid moieties, or mixtures thereof. Such linkers include (C_1-C_6) alkylene dihydrazides, (C_1-C_6) alkylene or arylene diamines, -aminoalkanoic acids, alkylene diols or oxyalkene diols or dithiols, cyclic amides and anhydrides and the like. For examples, see U.S. Pat. No. 5,739,313.

In accordance with the invention, a variety of methods known to those skilled in the art can be employed to make the conjugate vaccines. For example, any suitable functionalization reaction can be employed to activate the Phase 1 flagella protein with hydrazide groups. Conventional methods for preparing hydrazide-modified proteins include EDC (1-[3-(dimethylamino)propyl]-3-ethyl carbodiimide hydrochloride) catalysis and a two-step process using N-succinimidyl iodoacetate and thiol hydrazide through lysine ε-amino groups of the protein. See, e.g., King *et al.*, *Biochemistry* 1986; 25:5774-5779. In some embodiments, the modified protein prepared by EDC catalysis is fractionated in order for it to be suitable for use in conjugation. In some embodiments, hydrazide groups are introduced into proteins through the carboxyl groups of aspartic acid and glutamic acid residues on the protein using a carbodiimide reaction, for example, by reaction with hydrazine, carbohydrazide, succinyl dihydrazide, adipic acid dihydrazide or any other dihydrazides in the presence of EDC. In some embodiments, ADH can

be conjugated to CNBr activated OPS, followed by conjugation to flagellin protein through EDC mediated condensation onto carboxylic acid groups including but not limited to, glutamic acid and aspartic acid side chains. EDC is employed as a catalyst to activate and modify the protein reactant with hydrazine or the dihydrazide. Any water-soluble carbodiimide including EDC can be used as a catalyst. Under certain conditions, EDC-catalyzed proteins generally have a tendency to polymerize and precipitate. See Schneerson *et al.*, *Infect. Immun.* 1986, 52:519-528; Shafer *et al.*, *Vaccine* 2000; 18(13): 1273-1281; and Inman *et al.*, *Biochemistry* 1969; 8:4074-4082. Aggregation and precipitation of the activated protein depends, in part, on its pH environment. Accordingly, the tendency to polymerize and precipitate can be controlled by maintaining such hydrazide-modified proteins soluble in a buffered solution. By buffer-exchanging the reaction mixture so as to maintain the activated protein at a pH of about 10.5, the activated protein remains soluble and stable for conjugation. Any suitable buffer can be employed. In some embodiments, a weak buffer such as Na_2CO_3 at a low concentration of from about 3 mM to about 10 mM is employed.

In some embodiments, the buffered hydrazide-modified protein can then be employed in preparing protein-polysaccharide conjugates without precipitation when added to activated polysaccharide at a pH of from about 6 to 8.5, or from about 6.5 to about 8. Any suitable functionalization reaction can be employed to activate the protein with aldehyde groups. In some embodiments, the protein is reacted with 1-amino-2,3-propanediol in the presence of EDC. Amino sugars such as glucosamine, galactosamine, and the like can be used in place of 1-amino-2,3-propanediol. In this reaction, EDC is also employed as a catalyst to activate and modify the protein reactant with the aminodiol through the carboxyl groups of aspartic acid and glutamic acid residues of the protein.

In some embodiments, conjugates can be prepared via the reaction of aldehyde and hydrazide groups (reductive amination). The reductive amination conjugation reaction can be employed to conjugate a hydrazide-modified reactant (protein or polysaccharide) or unmodified protein through available amino groups including but not limited to lysine side chains, to the other component containing aldehyde groups. In some embodiments, the reductive amination conjugation

reaction proceeds without the aid of sodium cyanoborohydride because of the high efficiency of the hydrazide-aldehyde reaction. In some embodiments, at the end of the reductive amination conjugation reaction, sodium borohydride or another suitable reactant is employed to reduce the C=N double bond to a C-N single bond, as well as to reduce any residual aldehyde groups to alcohol groups. The reductive amination conjugation reaction in some embodiments avoids contamination of the resulting conjugate with cyanide, a by-product of sodium cyanoborohydride.

In some embodiments, during the conjugation process, the activated protein is in the form of a weakly buffered solution with a low buffer concentration of from about 3 mM to about 10 mM which is added to a strongly buffered (at pH of from about 6.5 to about 7.5, with a high buffer concentration of from about 100 mM to about 200 mM) activated polysaccharide solution. In some embodiments, the pH of the activated protein solution is buffered to from about 10 pH to about 11.5 pH, or in some embodiments to about 10.5 pH. In some embodiments, the activated polysaccharide solution is strongly buffered to from about 6 pH to about 8 pH, or from about 6.5 pH to about 7.5 pH. The hydrazide-aldehyde reductive amination reaction proceeds at a fast rate, and the precipitating effect of a pH lower than 10.5 (for example, a pH as low as from about 8.5 to about 9.5) on activated protein is overcome by the molecular properties of the reacting activated polysaccharide.

In some embodiments, the vaccine conjugates of the invention can be prepared via the reaction of hydrazide and cyanate groups (cyanalation conjugation). The cyanalation conjugation reaction is efficient and reversible, favoring the product formation. In certain embodiments, blocking agents are employed to remove residual cyanate groups. However, in other embodiments, addition of a blocking agent to the reaction mixture drives the conjugation reaction backward and reduces the conjugation yield. In some embodiments it can be desirable to employ blocking agents to quench the leftover residual cyanate groups, while in other embodiments their use is avoided. To remove residual cyanate groups in the conjugation product without using a blocking agent, the conjugation time can be prolonged.

In some embodiments of the invention, conjugation of OPS to flagellin is performed through activation of both OPS and flagellin. Activation of OPS can be accomplished by addition of carbonyldiimidazole to OPS in the presence of N,N-dimethylformamide and tetrabutylammonium, followed by reaction with

5   butyldiamine to form carbamate, and subsequent bromoacetylation to yield activated OPS. Activation of Flagellin can be achieved by reaction with N-acetylhomocysteine. Conjugation of activated OPS and flagellin molecules following this scheme can be accomplished by mixing at pH 8.

In some embodiments, conjugation is conducted at a temperature of from

10   about 0° C to about 5° C for about 36 to about 48 hours. In one embodiment, conjugation is conducted at about 4°C for about 36 hours, followed by about an additional 18 to 24 hours at a temperature of from about 20° C to about 25° C. In another embodiment, conjugation is conducted for about 18 hours at about 20 to 24° C, such that the residual cyanate groups react with water and decompose.

15   Longer or shorter conjugation times and/or higher or lower conjugation temperatures can be employed, as desired. In some embodiments, it is desirable, however, to conduct the conjugation reaction, at least initially, at low temperatures, for example, from about 0° C to about 5° C, such as about 4° C, so as to reduce the degree of precipitation of the conjugate.

20   In some embodiments of the invention, conjugation of OPS to flagellin protein is on the terminal amino group of lysine residues. In some embodiments of the invention, conjugation is to cysteine groups. In some embodiments of the invention of conjugation of the OPS is to N-terminal Serine groups. In some embodiments of the invention, conjugation of OPS to flagellin is directed towards

25   the C-terminal carboxylic acid group. In some embodiments of the invention, conjugation is to naturally occurring amino acid groups. In other embodiments of the invention, conjugation is to engineered amino acid sequences and residues within the flagellin protein.

In some embodiments of the invention, conjugation of flagellin to OPS is

30   on random free hydroxyl groups on the OPS polysaccharide chain. In some embodiments of the invention, conjugation of flagellin to OPS is at the terminal end of the polysaccharide chain.

In some embodiments of the invention, the OPS and Phase 1 flagella protein reactants contain multiple reactive groups per molecule. In some embodiments, an activated OPS molecule can react with and form more than one linkage to more than one activated Phase 1 flagella protein molecule. Likewise, an

5   activated Phase 1 flagella protein molecule can react with and form more than one linkage to more than one activated OPS molecule. Therefore, in some embodiments, the conjugate product is a mixture of various cross-linked matrix-type lattice structures. For example, a single linkage can be present, or 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29,

10   or 30 or more linkages can be present. The average number of linkages between an OPS and a Phase 1 flagella protein can be adjusted, as desired. In some embodiments, the average number of linkages can depend upon the type of OPS polysaccharide, the type of Phase I flagella protein, the conjugation method, the reaction conditions, and the like. In some embodiments, an average of 1 linkage to

15   about 2, 3, 4, or 5 linkages is present, so as to avoid interfering with the ability of the FliC protein to stimulate the innate immune system via TLR5 by over-conjugation, and so as to not cause changes in the polysaccharide structure. However, in certain embodiments more than 5 linkages can be tolerated.

In some embodiments, purification processes such as column

20   chromatography and/or ammonium sulfate precipitation of the conjugate from unconjugated polysaccharide may not be necessary. However, in certain embodiments it can be desirable to conduct one or more purification steps. In some embodiments, after conjugation, the conjugate can be purified by any suitable method. Purification is employed to remove unreacted polysaccharide,

25   protein, or small molecule reaction byproducts. Purification methods include ultrafiltration, size exclusion chromatography, density gradient centrifugation, hydrophobic interaction chromatography, ammonium sulfate fractionation, ion exchange chromatrography, ligand exchange chromatography, immuno-affinity chromatography, polymyxin-b chromatography, and the like, as are known in the

30   art. In some embodiments, the conjugation reactions proceed with higher yield, and generate fewer undesirable small molecule reaction byproducts. Accordingly, in some embodiments no purification may be necessary, or only a minor degree of

purification can be desirable. The conjugate can be concentrated or diluted, or processed into any suitable form for use in pharmaceutical compositions, as desired. Purification of OPS-flagellin conjugates has been demonstrated with the use of size exclusion chromatography (FIG. 10).

5   There are many coupling methods which can be envisioned for OPS-Phase 1 flagella protein conjugates. Other methods well known in the art for effecting conjugation of oligosaccharides to immunogenic carrier proteins are also within the scope of the invention. Such methods are described in, for example, U.S. Pat. Nos. 5,153,312 and 5,204,098; EP 0 497 525; and EP 0 245 045, the entire

10   disclosures of which are hereby incorporated by reference.

Pharmaceutical Compositions of the Conjugate Vaccine

As would be understood by one of ordinary skill in the art, when the conjugate vaccine of the present invention is provided to an individual, it may be in a

15   composition which may contain salts, buffers, adjuvants, or other substances which are desirable for improving the efficacy of the composition. Adjuvants are substances that can be used to specifically augment a specific immune response. Normally, the adjuvant and the composition are mixed prior to presentation to the immune system, or presented separately, but into the same site of the animal being

20   immunized. Adjuvants can be loosely divided into several groups based upon their composition. These groups include oil adjuvants (for example, Freund's complete and incomplete), mineral salts (for example, $AlK(SO_4)_2$, $AlNa(SO_4)_2$, $AlNH_4$ (SO_4), silica, kaolin, and carbon), polynucleotides (for example, poly IC and poly AU acids), and certain natural substances (for example, wax D from

25   *Mycobacterium tuberculosis*, as well as substances found in *Corynebacterium parvum*, or *Bordetella pertussis*, and members of the genus *Brucella*. Adjuvants are described by Warren *et al.* (*Ann. Rev. Biochem.*, 4:369-388, 1986), the entire disclosure of which is hereby incorporated by reference. Bacterial flagellin and flagellin fusion proteins have been demonstrated previously to be a potent adjuvant

30   in mice and non-human primates (Mizel *et al.* 2009. *Clinical and Vaccine Immunology.* 16(1):21-28; McSorley *et al.* 2002. *The Journal of Immunology.* 169:3914-3919; Huleat *et al.* 2008. *Vaccine.* 26(2):201-214).

In some embodiments of the invention the use of flagellin protein as a carrier for OPS conjugate provides an inherent adjuvant boost, and stimulates a robust immune response without the addition of further adjuvant. Thus, in some

5   embodiments, the flagellin protein acts an adjuvant which stimulates innate immunity through TLR5 to improve the immunogenicity of OPS within the conjugate vaccine.

In other embodiments, conventional adjuvants can be administered. Among those substances particularly useful as adjuvants are the saponins such as,

10   for example, Quil A. (Superfos A/S, Denmark). In some embodiments, immunogenicity of the conjugates in both mice and rabbits is enhanced by the use of monophosphoryl lipid A plus trehalose dimycolate (Ribi-700; Ribi Immunochemical Research, Hamilton, Mont.) as an adjuvant. Examples of materials suitable for use in vaccine compositions are provided in *Remington's*

15   *Pharmaceutical Sciences* (Osol, A, Ed, Mack Publishing Co, Easton, Pa., pp. 1324-1341 (1980), which disclosure is incorporated herein by reference).

The conjugate vaccines can be formulated into liquid preparations for, e.g., nasal, rectal, buccal, vaginal, peroral, intragastric, mucosal, perlinqual, alveolar, gingival, olfactory, or respiratory mucosa administration. Suitable forms for such

20   administration include solutions, suspensions, emulsions, syrups, and elixirs. The conjugate vaccines can also be formulated for parenteral, subcutaneous, intradermal, intramuscular, intraperitoneal or intravenous administration, injectable administration, sustained release from implants, or administration by eye drops. Suitable forms for such administration include sterile suspensions and emulsions.

25   Such conjugate vaccines can be in admixture with a suitable carrier, diluent, or excipient such as sterile water, physiological saline, glucose, and the like. The conjugate vaccines can also be lyophilized. The conjugate vaccines can contain auxiliary substances such as wetting or emulsifying agents, pH buffering agents, gelling or viscosity enhancing additives, preservatives, flavoring agents, colors,

30   and the like, depending upon the route of administration and the preparation desired. Texts, such as *Remington: The Science and Practice of Pharmacy*, Lippincott Williams & Wilkins; 20th edition (Jun. 1, 2003) and *Remington's*

26

Pharmaceutical Sciences, Mack Pub. Co.; 18th and 19th editions (December 1985, and June 1990, respectively), incorporated herein by reference in their entirety, can be consulted to prepare suitable preparations. Such preparations can include complexing agents, metal ions, polymeric compounds such as polyacetic acid,

5   polyglycolic acid, hydrogels, dextran, and the like, liposomes, microemulsions, micelles, unilamellar or multilamellar vesicles, erythrocyte ghosts or spheroblasts. Suitable lipids for liposomal formulation include, without limitation, monoglycerides, diglycerides, sulfatides, lysolecithin, phospholipids, saponin, bile acids, and the like. The presence of such additional components can influence the

10   physical state, solubility, stability, rate of in vivo release, and rate of in vivo clearance, and are thus chosen according to the intended application, such that the characteristics of the carrier are tailored to the selected route of administration.

In some embodiments, the conjugate vaccine of the invention is administered parenterally. Parenteral vehicles include sodium chloride solution,

15   Ringer's dextrose, dextrose and sodium chloride, lactated Ringer's or fixed oils. Intravenous vehicles include fluid and nutrient replenishers, electrolyte replenishers (such as those based on Ringer's dextrose), and the like. In some embodiments, the OPS-Phase 1 flagella protein conjugates for parenteral administration may be in the form of a sterile injectable preparation, such as a

20   sterile injectable aqueous or nonaqueous solutions, suspensions, and emulsions. Examples of non-aqueous solvents are propylene glycol, polyethylene glycol, vegetable oils such as olive oil, and injectable organic esters such as ethyl oleate. Carriers or occlusive dressings can be used to increase skin permeability and enhance antigen absorption. Suspensions may be formulated according to methods

25   well known in the art using suitable dispersing or wetting agents and suspending agents. The sterile injectable preparation may also be a sterile injectable solution or suspension in a parenterally acceptable diluent or solvent, such as a solution in 1,3-butanediol. Suitable diluents include, for example, water, Ringer's solution and isotonic sodium chloride solution. In addition, sterile fixed oils may be employed

30   conventionally as a solvent or suspending medium. For this purpose, any bland fixed oil may be employed including synthetic mono- or diglycerides. In addition,

fatty acids such as oleic acid may likewise be used in the preparation of injectable preparations.

Liquid dosage forms for oral administration may generally comprise a liposome solution containing the liquid dosage form. Suitable forms for suspending liposomes include emulsions, suspensions, solutions, syrups, and elixirs containing inert diluents commonly used in the art, such as purified water. Besides the inert diluents, such compositions can also include adjuvants, wetting agents, emulsifying and suspending agents, or sweetening, flavoring, or perfuming agents.

In some embodiments, the conjugate vaccines are provided as liquid suspensions or as freeze-dried products. Suitable liquid preparations include, e.g., isotonic aqueous solutions, suspensions, emulsions, or viscous compositions that are buffered to a selected pH. Transdermal preparations include lotions, gels, sprays, ointments or other suitable techniques. If nasal or respiratory (mucosal) administration is desired (e.g., aerosol inhalation or insufflation), compositions can be in a form and dispensed by a squeeze spray dispenser, pump dispenser or aerosol dispenser. Aerosols are usually under pressure by means of a hydrocarbon. Pump dispensers can preferably dispense a metered dose or a dose having a particular particle size, as discussed below.

When in the form of solutions, suspensions and gels, in some embodiments, the formulations of the conjugate contain a major amount of water (preferably purified water) in addition to the active ingredient. Minor amounts of other ingredients such as pH adjusters, emulsifiers, dispersing agents, buffering agents, preservatives, wetting agents, jelling agents, colors, and the like can also be present.

In some embodiments, the compositions are preferably isotonic with the blood or other body fluid of the recipient. The isotonicity of the compositions can be attained using sodium tartrate, propylene glycol or other inorganic or organic solutes. Sodium chloride is particularly preferred. Buffering agents can be employed, such as acetic acid and salts, citric acid and salts, boric acid and salts, and phosphoric acid and salts. In some embodiments of the invention, phosphate buffered saline is used for suspension.

In some embodiments, the viscosity of the compositions can be maintained at the selected level using a pharmaceutically acceptable thickening agent. In some embodiments, methylcellulose is used because it is readily and economically available and is easy to work with. Other suitable thickening agents include, for example, xanthan gum, carboxymethyl cellulose, hydroxypropyl cellulose, carbomer, and the like. The concentration of the thickener can depend upon the agent selected. In some embodiments, viscous compositions are prepared from solutions by the addition of such thickening agents.

In some embodiments, a pharmaceutically acceptable preservative can be employed to increase the shelf life of the compositions. Benzyl alcohol can be suitable, although a variety of preservatives including, for example, parabens, thimerosal, chlorobutanol, or benzalkonium chloride can also be employed. A suitable concentration of the preservative can be from 0.02% to 2% based on the total weight although there can be appreciable variation depending upon the agent selected.

In some embodiments, pulmonary delivery of the conjugate can also be employed. In some embodiments, the conjugate is delivered to the lungs of a mammal while inhaling and traverses across the lung epithelial lining to the blood stream. A wide range of mechanical devices designed for pulmonary delivery of therapeutic products can be employed, including but not limited to nebulizers, metered dose inhalers, and powder inhalers, all of which are familiar to those skilled in the art. These devices employ formulations suitable for the dispensing of the conjugate. Typically, each formulation is specific to the type of device employed and can involve the use of an appropriate propellant material, in addition to diluents, adjuvants and/or carriers useful in therapy.

In embodiments where the conjugate is prepared for pulmonary delivery in particulate form, it has an average particle size of from 0.1 μm or less to 10 μm or more. In some embodiments, it has an average particle size of from about 0.2, 0.3, 0.4, 0.5, 0.6, 0.7, 0.8, or 0.9 μm to about 1.0, 1.5, 2.0, 2.5, 3.0, 3.5, 4.0, 4.5, 5.0, 5.5, 6.0, 6.5, 7.0, 7.5, 8.0, 8.5, 9.0, or 9.5 μm for pulmonary delivery. Pharmaceutically acceptable carriers for pulmonary delivery of the conjugates include carbohydrates such as trehalose, mannitol, xylitol, sucrose, lactose, and

sorbitol. Other ingredients for use in formulations can include DPPC, DOPE, DSPC and DOPC. Natural or synthetic surfactants can be used, including polyethylene glycol and dextrans, such as cyclodextran and other related enhancers, as well as cellulose and cellulose derivatives, and amino acids can also be used. Liposomes, microcapsules, microspheres, inclusion complexes, and other types of carriers can also be employed.

Formulations suitable for use with a nebulizer, either jet or ultrasonic, typically comprise the conjugate dissolved or suspended in water at a concentration of about 0.01 or less to 100 mg or more of conjugate per mL of solution, preferably from about 0.1, 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 mg to about 15, 20, 25, 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, or 90 mg of conjugate per mL of solution. The formulation can also include a buffer and a simple sugar (e.g., for protein stabilization and regulation of osmotic pressure). The nebulizer formulation can also contain a surfactant, to reduce or prevent surface induced aggregation of the conjugate caused by atomization of the solution in forming the aerosol.

Formulations for use with a metered-dose inhaler device generally comprise a finely divided powder containing the inventive compound suspended in a propellant with the aid of a surfactant. The propellant can include conventional propellants, such chlorofluorocarbon, a hydrochlorofluorocarbons, hydrofluorocarbons, and hydrocarbons, such as trichlorofluoromethane, dichlorodifluoromethane, dichlorotetrafluoroethanol, and 1,1,1,2-tetrafluoroethane, and combinations thereof. Suitable surfactants include sorbitan trioleate, soya lecithin, and oleic acid.

Formulations for dispensing from a powder inhaler device typically comprise a finely divided dry powder containing the conjugate, optionally including a bulking agent, such as lactose, sorbitol, sucrose, mannitol, trehalose, or xylitol in an amount that facilitates dispersal of the powder from the device, typically from about 1 wt. % or less to 99 wt. % or more of the formulation, preferably from about 5, 10, 15, 20, 25, 30, 35, 40, 45, or 50 wt. % to about 55, 60, 65, 70, 75, 80, 85, or 90 wt. % of the formulation.

Attenuated *Salmonella* Strains

The present invention further relates to an attenuated *S.* Enteritidis or *S.* Typhimurium strain. In some embodiments, the attenuated strains may be used to induce an immune response in a subject without causing disease in the subject.

5   In some embodiments, *S.* Enteritidis strain R11 and S. Typhimurium strain I77 are used as starting material strains. The *S.* Enteritidis or *S.* Typhimurium strains of the present invention are attenuated. As used herein, attenuated strains are those that have a reduced, decreased, or suppressed ability to cause disease in a subject, or those completely lacking in the ability to cause disease in a subject.

10   Attenuated strains may exhibit reduced or no expression of one or more genes, may express one or more proteins with reduced or no activity, may exhibit a reduced ability to grow and divide, or a combination of two or more of these characteristics. The attenuated strains of the present invention may be living or dead.

15   In some embodiments, the attenuated *S.* Enteritidis or *S.* Typhimurium strains of the present invention have a mutation in one or more of the *guaBA* locus, the *guaB* gene, the *guaA* gene, the *clpP* gene, the *clpX* gene and the *clpPX* locus. For example, the attenuated *S.* Enteritidis and *S.* Typhimurium strains of the present invention may have a mutation (i) in the *guaB* gene and the *clpP* gene, (ii)

20   in the *guaA* gene and the *clpP* gene, (iii) in the *guaBA* locus, and the *clpP* gene, (iv) in the *guaB* gene and the *clpX* gene, (v) in the *guaA* gene and the *clpX* gene, (vi) in the *guaBA* locus, and the *clpX* gene, (vii) in the *guaB* gene and the *clpPX* locus, (viii) in the *guaA* gene and the *clpPX* locus, or (ix) in both the *guaBA* locus and the *clpPX* locus In one embodiment, attenuated *S.* Enteritidis or *S.*

25   Typhimurium strains are prepared having chromosomal deletions in both the *guaBA* locus (encoding enzymes involved in guanine nucleotide biosynthesis) and the *clpPX* locus (encoding an important metabolic ATPase) genes. The mutations of the loci and genes described herein may be any mutation, such as one or more nucleic acid deletions, insertions or substitutions. The mutations may be any

30   deletion, insertion or substitution of the loci or genes that results in a reduction or absence of expression from the loci or genes, or a reduction or absence of activity

31

of a polypeptide encoded by the loci or genes. The mutations may be in the coding or non-coding regions of the loci or genes.

In some embodiments, the chromosomal genome of the *S.* Enteritidis or *S.* Typhimurium strain is modified by removing or otherwise modifying the *guaBA* locus, and thus blocking the *de novo* biosynthesis of guanine nucleotides. In some embodiments, a mutation in the *guaBA* locus inactivates the purine metabolic pathway enzymes IMP dehydrogenase (encoded by *guaB*) and GMP synthetase (encoded by *guaA*). In some embodiments, the strains are unable to *de novo* synthesize GMP, and consequently GDP and GTP nucleotides, which severely limits bacterial growth in mammalian tissues. In some embodiments, the Δ*guaBA* *S.* Enteritidis or *S.* Typhimurium mutants of the present invention are unable to grow in minimal medium unless supplemented with guanine. In some embodiments, the Δ*guaBA* *S.* Enteritidis or *S.* Typhimurium mutants of the present invention show a significant reduction in their capability for replication in tissue culture cells after invasion. In some embodiments, Δ*guaBA* *S.* Enteritidis or *S.* Typhimurium mutants may scavenge guanine nucleotides from the tissues of the mammalian host. However, their assimilation into *S.* Enteritidis or *S.* Typhimurium requires prior dephosphorylation to nucleosides by periplasmic nucleotidases to be incorporated as nucleotide precursors into the guanine salvage pathway. Therefore, as nucleotides are readily available in the intracellular environment of the mammalian host, the attenuation due to the *de novo* synthesis of guanine nucleotides is due either to the inefficiency of the salvage pathway or to reasons that are obscure to today's knowledge.

The *guaA* gene of *S.* Enteritidis, which encodes GMP synthetase, is 1578 bp in size (GenBank Accession Number NC_011294 REGION: 2623838-2625415) (SEQ ID NO:1). The *guaA* gene of *S.* Typhimurium, is 1578 bp in size (GenBank Accession Number NC_003197 REGION: 2622805-2624382) (SEQ ID NO:2). Deletion mutants can be produced by eliminating portions of the coding region of the *guaA* gene of *S.* Enteritidis or *S.* Typhimurium so that proper folding or activity of GuaA is prevented. For example, about 25 to about 1500 bp, about 75 to about 1400 bp, about 100 to about 1300 bp, or all of the coding region can be deleted. Alternatively, the deletion mutants can be produced by eliminating, for

example, a 1 to 100 bp fragment of the *guaA* gene of *S.* Enteritidis or *S.* Typhimurium so that the proper reading frame of the gene is shifted. In the latter instance, a nonsense polypeptide may be produced or polypeptide synthesis may be aborted due to a frame-shift-induced stop codon. The preferred size of the deletion removes both *guaB* and *guaA*, from the ATG start codon of *guaB* to the stop codon of *guaA*. Deletions can also be made that extend beyond the *guaA* gene.

The *guaB* gene of *S.* Enteritidis which encodes IMP dehydrogenase, is 1467 bp in size (GenBank Accession Number NC_011294 REGION: 2625485-2626951) bp in size (SEQ ID NO:3). The *guaB* gene of *S.* Typhimurium is 1467 bp in size (GenBank Accession Number NC_003197 REGION: 2624452-2625918) (SEQ ID NO:4). Deletion mutants can be produced by eliminating portions of the coding region of the *guaB* gene of *S.* Enteritidis or *S.* Typhimurium so that proper folding or activity of GuaB is prevented. For example, about 25 to about 1400 bp, about 75 to about 1300 bp, about 100 to about 1200 bp, or all of the coding region can be deleted. Alternatively, the deletion mutants can be produced by eliminating, for example, a 1 to 100 bp fragment of the *guaB* gene of *S.* Enteritidis or *S.* Typhimurium so that the proper reading frame of the gene is shifted. In the latter instance, a nonsense polypeptide may be produced or polypeptide synthesis may be aborted due to a frame-shift-induced stop codon. The preferred size of the deletion removes both *guaB* and *guaA*, from the ATG start codon of *guaB* to the stop codon of *guaA*. In some embodiments, deletions can also be made that extend beyond the *guaB* gene.

The *clpP* gene of *S.* Enteritidis, which encodes a serine-protease, is 624 bp in size (GenBank Accession Number NC_011294 REGION: 482580-483203) (SEQ ID NO:5). The *clpP* gene of *S.* Typhimurium is 624 bp in size (GenBank Accession Number NC_003197 REGION: 503210-503833) (SEQ ID NO:6). Deletion mutants can be produced by eliminating portions of the coding region of the *clpP* gene of *S.* Enteritidis or *S.* Typhimurium so that proper folding or activity of ClpP is prevented. For example, about 25 to about 600 bp, about 75 to about 500 bp, about 100 to about 400 bp, or all of the coding region can be deleted. Alternatively, the deletion mutants can be produced by eliminating, for example, a 1 to 100 bp fragment of the *clpP* gene of *S.* Enteritidis or *S.*

Typhimurium so that the proper reading frame of the gene is shifted. In the latter instance, a nonsense polypeptide may be produced or polypeptide synthesis may be aborted due to a frame-shift-induced stop codon. The preferred size of the deletion is about 25 to 600 bp. Deletions can also be made that extend beyond the *clpP*

5   gene.

The *clpX* gene of *S.* Enteritidis, which encodes a chaperone ATPase, is 1272 bp in size (GenBank Accession Number NC_011294 REGION: 483455-484726) (SEQ ID NO:7). The *clpX* gene of *S.* Typhimurium is 1272 bp in size (GenBank Accession Number NC_003197 REGION: 504085-505356) (SEQ ID

10   NO:8). Deletion mutants can be produced by eliminating portions of the coding region of the *clpX* gene of *S.* Enteritidis or *S.* Typhimurium so that proper folding or activity of ClpX is prevented. For example, about 25 to about 1200 bp, about 75 to about 1100 bp, about 100 to about 1000 bp, or all of the coding region can be deleted. Alternatively, the deletion mutants can be produced by eliminating, for

15   example, a 1 to 100 bp fragment of the *clpX* gene of *S.* Enteritidis or *S.* Typhimurium so that the proper reading frame of the gene is shifted. In the latter instance, a nonsense polypeptide may be produced or polypeptide synthesis may be aborted due to a frame-shift-induced stop codon. The preferred size of the deletion is about 75 to 750 bp. Deletions can also be made that extend beyond the *clpX*

20   gene.

In some embodiments, deletions can be made in any of the loci or genes included herein by using convenient restriction sites located within the loci or genes, or by site-directed mutagenesis with oligonucleotides (Sambrook *et al.*, *Molecular Cloning, A Laboratory Manual*, Eds., Cold Spring Harbor Publications

25   (1989)).

In some embodiments, inactivation of the loci or genes can also be carried out by an insertion of foreign DNA using any convenient restriction site, or by site-directed mutagenesis with oligonucleotides (Sambrook *et al.*, supra) so as to interrupt the correct transcription of the loci or genes. The typical size of an

30   insertion that can inactivate the loci or genes is from 1 base pair to 100 kbp, although insertions smaller than 100 kbp are preferable. The insertion can be made

34

anywhere inside the loci or gene coding regions or between the coding regions and the promoters.

Other methods for the inactivation of the loci and genes include the transfer into *Salmonella* of deletions or insertions made in other enterobacteriaceae *guaBA*

5   locus, *guaA*, *guaB*, *clpP* or *clpX* genes, or *clpPX locus*, transposon-generated deletions, and imprecise excision of DNA insertions.

In some_embodiments, the bacterial loci and genes are mutated using Lambda Red-mediated mutagenesis (Datsenko and Wanner, *PNAS USA* 97:6640-6645 (2000)). Briefly, in step 1 host bacteria targeted for mutation are transformed

10   with a temperature sensitive plasmid encoding lambda Red recombinase. These bacteria are grown in the presence of arabinose to induce lambda Red production. Chromosomal mutagenesis of a target sequence is accomplished by electroporation of the host with linear DNA in which the target gene is replaced with an antibiotic resistance marker. This DNA also encodes short regions of flanking chromosomal

15   sequences to allow for chromosomal integration of the resistance marker by lambda Red–mediated homologous recombination. Recombinants are selected for on solid media containing the appropriate antibiotic, and incubated at a temperature facilitating the loss of the plasmid encoding lambda Red recombinase. For step 2, removal of the chromosomal resistance marker is facilitated by

20   transforming the bacteria with a temperature sensitive plasmid encoding FLP recombinase, which targets unique FRT recombination sites engineered to flank the antibiotic resistance marker now present in the host chromosome. Transformants are grown at temperatures permissive for the presence of the FLP recombinase which is expressed constitutively. In some embodiments, mutants are

25   screened via PCR, grown at a temperature to facilitate loss of the plasmid encoding FLP recombinase, and selected for storage.

In some embodiments, the attenuated *S.* Enteritidis or *S.* Typhimurium strains of the present invention may contain mutations in one or more additional genes. While an extensive discussion of additional attenuating mutations of

30   *Salmonella* spp. is provided in U.S. Patent No. 6,682,729, exemplary genes include those encoding various biochemical pathways, global regulatory systems, heat shock proteins, other regulatory genes, and putative virulence properties. Specific

examples of such attenuating mutations include, but are not limited to: (i) auxotrophic mutations, such as *aro*, *nad*, *thy*, and *asd* mutations; (ii) mutations that inactivate global regulatory functions, such as *cya*, *crp*, *phoP/phoQ*, *phoP^c* and *ompR* mutations; (iii) mutations that modify the stress response, such as *recA*, *htrA*,

5   *htpR*, *hsp* and *groEL* mutations; (iv) mutations in specific virulence factors, such as *pag* and *prg* (v) mutations that affect DNA topology, such as *topA* mutations; (vi) mutations that modify suicide systems, such as *sacB*, *nuc*, *hok*, *gef*, *kil*, and *phlA* mutations; (vii) mutations that introduce suicide systems, such as lysogens encoded by *P22*, λ murein transglycosylase and S-gene; and (viii) mutations that disrupt or

10   modify the correct cell cycle, such as *minB* mutations. Such mutations are permissible, provided however, that such mutations do not inactivate loci involved in generation of surface polysaccharides which would alter the surface OPS immunogens.

15   Formulations, Dosages and Modes of Administering the Attenuated Strains

The attenuated strains of the present invention may be administered to a subject to induce an immune response. In one embodiment, the strains of the present invention are administered in a pharmaceutical formulation.

The pharmaceutical formulations of the strains of the present invention may

20   include pharmaceutically acceptable carriers, excipients, other ingredients, such as adjuvants. Pharmaceutically acceptable carriers, excipients, other ingredients are those compounds, solutions, substances or materials that are compatible with the strains of the present invention and are not unduly deleterious to the recipient thereof, or diminish intended immune responses. In particular, carriers, excipients,

25   other ingredients of the present invention are those useful in preparing a pharmaceutical formulation that is generally safe, non-toxic and neither biologically nor otherwise undesirable, and that may present pharmacologically favorable profiles, and includes carriers, excipients, other ingredients that are acceptable for veterinary use as well as human pharmaceutical use.

30   Suitable pharmaceutically acceptable carriers and excipients are well known in art and can be determined by those of skill in the art as the clinical

situation warrants. The skilled artisan will understand that diluents are included within the scope of the terms carriers and excipients. Examples of suitable carriers and excipients include saline, buffered saline, dextrose, water, glycerol, ethanol, more particularly: (1) Dulbecco's phosphate buffered saline, pH about 7.4,

5   containing about 1 mg/ml to 25 mg/ml human serum albumin, (2) 0.9% saline (0.9% w/v NaCl), (3) 5% (w/v) dextrose, and (4) water.

The mode of administration of the immunizing compositions of the present invention may be any suitable delivery means and/or methods that results in the induction of an immune response in the subject. Delivery means may include, non-

10   parenteral, e.g., oral, nasal, intravaginal, pulmonary (inhalation), ophthalmic, rectal administration, or by any other mode that results in the immunogenic composition contacting mucosal tissues. In one embodiment, one or more attenuated strains are administered orally.

In one embodiment of the present invention, the immunizing compositions

15   exist as an atomized dispersion for delivery by inhalation. Various liquid and powder formulations can be prepared by conventional methods for inhalation into the lungs of the subject to be treated. The atomized dispersion of the immunizing compositions typically contains carriers common for atomized or aerosolized dispersions, such as buffered saline and/or other compounds well known to those

20   of skill in the art. The delivery of the immunogenic compositions via inhalation has the effect of rapidly dispersing the immunizing compositions to a large area of mucosal tissues.

Additionally, immunizing compositions also exist in a liquid form. The liquid can be for oral dosage, for ophthalmic or nasal dosage as drops, or for use as

25   an enema or douche. When the immunizing composition is formulated as a liquid, the liquid can be either a solution or a suspension of the immunizing composition. There are a variety of suitable formulations for the solution or suspension of the immunizing composition that are well know to those of skill in the art, depending on the intended use thereof. Liquid formulations for oral administration prepared in

30   water or other aqueous vehicles may contain various suspending agents such as methylcellulose,   alginates,   tragacanth,   pectin,   kelgin,   carrageenan,   acacia,

polyvinylpyrrolidone, and polyvinyl alcohol. The liquid formulations may also include solutions, emulsions, syrups and elixirs containing, together with the immunizing compositions, wetting agents, sweeteners, and coloring and flavoring agents.

5   Delivery of the described immunizing compositions in liquid form via oral, rectal, and vaginal dosage exposes the mucosa of the gastrointestinal and urogenital tracts to the immunizing compositions. A suitable dose, stabilized to resist the pH extremes of the stomach, delivers the immunizing composition to all parts of the gastrointestinal tract, especially the upper portions thereof. Any

10   methods of stabilizing the immunizing composition in a liquid oral dosage such that the effective delivery of the composition is distributed along the gastrointestinal tract are contemplated for use with the immunizing compositions described herein, including capsules and a resuspended buffer solution to protect the attenuated bacteria against the acidic pH. The particular pharmaceutically

15   acceptable carriers or diluents employed are not critical to the present invention, and are conventional in the art. Examples of diluents include: buffers for buffering against gastric acid in the stomach, such as citrate buffer (pH 7.0) containing sucrose, bicarbonate buffer (pH 7.0) alone or bicarbonate buffer (pH 7.0) containing ascorbic acid, lactose, and optionally aspartame (Levine et al, Lancet,

20   II:467-470 (1988)). Examples of carriers include: proteins, e.g., as found in skim milk; sugars, e.g., sucrose; or polyvinylpyrrolidone.

Delivery of the described immunizing strains in liquid form via ophthalmic drops exposes the mucosa of the eyes and associated tissues to the immunizing compositions. A typical liquid carrier for eye drops is buffered and contains other

25   compounds well known and easily identifiable to those of skill in the art.

Delivery of the described immunizing compositions in liquid form via nasal drops or aerosol exposes the mucosa of the nose and sinuses and associated tissues to the immunizing compositions. Liquid carriers for nasal drops are typically various forms of buffered saline.

30   The attenuated *S.* Typhimurium and *S.* Enteritidis strains of the present invention may be administered to a subject in conjunction with other suitable

pharmacologically or physiologically active agents, e.g., antigenic and/or other biologically active substances.

The amount and rate of administration of the immunizing compositions of the present invention may be readily determined by those of ordinary skill in the art without undue experimentation, such as by use of conventional antibody titer determination techniques and conventional bioefficacy/biocompatibility protocols employed after vaccination. The amount and rate of administration will vary based on factors such as the weight and health of the subject, the identity of the bacteria being administered to the subject, the identity of the polypeptide being expressed in those strains engineered to express a selected antigen, the desired therapeutic effect, the desired time span of bioactivity, and the mode of administration of the immunizing composition.

In general, the amount of an immunizing composition administered to a subject is an amount sufficient to induce an immune response in the subject to a *S.* Typhimurium or *S.* Enteritidis strain or to the selected antigen being expressed by the *S.* Typhimurium or *S.* Enteritidis strain (an immunologically-effective amount). In a preferred embodiment, the immune response is a protective immune response.

In some embodiments, the dosage employed for mucosal delivery will contain about 10^5 cfu to 10^{10} cfu of the *S.* Typhimurium or *S.* Enteritidis strain, preferably about 10^5 cfu to 10^7 cfu, or about 10^6 cfu to 10^9 cfu. Formulations for oral administration comprise about 10^6 cfu to 10^{10} cfu of the *S.* Typhimurium or *S.* Enteritidis strain, preferably about 10^8 cfu to 10^9 cfu, and the formulation is in a capsule or resuspended in a buffer solution to protect the attenuated bacteria against the acidic pH in the stomach. Formulations for nasal administration comprise about 10^5 cfu to 10^{10} cfu of the *S.* Typhimurium or *S.* Enteritidis strain, preferably about 10^7 cfu to 10^8 cfu, and is used for intranasal administration in which the bacteria is given in drops or in aerosol.

The immunizing compositions of *S.* Typhimurium or *S.* Enteritidis strains of the invention may be administered in a single dose, or in multiple doses over prolonged periods of time. In particular, the immunizing compositions may be administered over a period of one week, two weeks, three weeks, one month, six

weeks, two months, ten weeks, three months, four months, six months, one year, or for extended periods longer than one year.

The immunizing compositions of *S*. Typhimurium or *S*. Enteritidis may be provided in dosage units for uniform dosage and ease of administration. Each dosage unit form contains a predetermined quantity of the strains of the present invention calculated to produce a desired immune response, in association with a pharmaceutically acceptable carrier, excipient, or other ingredient.

In some embodiments, the compositions of *S*. Typhimurium or *S*. Enteritidis are administered as live vaccines. In other embodiments, the *S*. Typhimurium or *S*. Enteritidis are killed formulations, e.g., by heat, prior to administration.

Methods of Inducing an Immune Response

The present invention also includes methods of inducing an immune response in a subject. The immune response may be to the attenuated *S*. Typhimurium or *S*. Enteritidis strains, a conjugate vaccine of the invention, or both.

Vaccine strategies are well known in the art and therefore the vaccination strategy encompassed by the invention does not limit the invention in any manner. In certain aspects of the invention, the conjugate vaccine is administered alone in a single dose or administered in sequential doses. In other aspects of the invention, the conjugate vaccine is administered as a component of a homologous or heterologous prime/boost regimen. In some embodiments of the invention, a single boost is used. In some embodiments of the invention, multiple boost immunizations are performed. In particular aspects of the invention drawn to heterologous prime/boost, a mucosal bacterial prime/parenteral conjugate boost immunization strategy is used. For example, one or more attenuated *S*. Typhimurium or *S*. Enteritidis strains as taught herein is administered orally and subsequently boosted parentally with a conjugate vaccine of homologous OPS from *S*. Typhimurium or *S*. Enteritidis and a homologous flagellin protein from *S*. Typhimurium or *S*. Enteritidis as described herein.

40

In one embodiment, the method of inducing an immune response comprises administering one or more of the *S.* Typhimurium or *S.* Enteritidis strains of the present invention to a subject in an amount sufficient to induce an immune response in the subject.

5   In a further embodiment, the method of inducing an immune response comprises administering a pharmaceutical formulation comprising one or more of the strains of the present invention to a subject in an amount sufficient to induce an immune response in the subject (an immunologically-effective amount).

In a further embodiment, the method of inducing an immune response
10   comprises administering a conjugate vaccine of the present invention to a subject in an amount sufficient to induce an immune response in the subject (an immunologically-effective amount).

As used herein, an "immune response" is the physiological response of the subject's immune system to an immunizing composition. An immune response
15   may include an innate immune response, an adaptive immune response, or both. In some embodiments of the present invention, the immune response is a protective immune response. A protective immune response confers immunological cellular memory upon the subject, with the effect that a secondary exposure to the same or a similar antigen is characterized by one or more of the following characteristics:
20   shorter lag phase than the lag phase resulting from exposure to the selected antigen in the absence of prior exposure to the immunizing composition; production of antibody which continues for a longer period than production of antibody resulting from exposure to the selected antigen in the absence of prior exposure to the immunizing composition; a change in the type and quality of antibody produced in
25   comparison to the type and quality of antibody produced upon exposure to the selected antigen in the absence of prior exposure to the immunizing composition; a shift in class response, with IgG antibodies appearing in higher concentrations and with greater persistence than IgM, than occurs in response to exposure to the selected antigen in the absence of prior exposure to the immunizing composition;
30   an increased average affinity (binding constant) of the antibodies for the antigen in comparison with the average affinity of antibodies for the antigen resulting from exposure to the selected antigen in the absence of prior exposure to the immunizing

composition; and/or other characteristics known in the art to characterize a secondary immune response.

In some embodiments, the invention is directed to methods of inducing an immune response, comprising administering to a subject in need thereof an effective amount of a conjugate vaccine comprising an O polysaccharide (OPS) and a flagellin protein or a fragment or a derivative thereof, wherein the OPS and flagellin protein of the conjugate vaccine are characteristic of group B or group D *Salmonella* serovars, such as *S.* Typhimurium, or *S.* Enteritidis, respectively.

In some embodiments, the invention is directed to methods of inducing an immune response, comprising administering to a subject in need thereof a vaccine comprising an immunologically-effective amount of genetically modified attenuated *Salmonella* serovar as described herein selected from the group consisting of S. Typhimurium and S. Enteritidis.

In another aspect, the invention is directed to methods of inducing an immune response, comprising administering to a subject in need thereof a first vaccine comprising an immunologically-effective amount of genetically modified attenuated *Salmonella* serovar as described herein and a second vaccine comprising an immunologically-effective amount of a conjugate comprising the homologous OPS and flagellin protein or a fragment or a derivative thereof. In one embodiment, a subject is orally administered an attenuated live strain of *S.* Typhimurium and/or *S.* Enteritidis of the invention, followed by a booster immunization administered parenterally, comprising a conjugate vaccine of the invention, wherein the conjugate vaccine is a *Salmonella* Group B and/or D OPS covalently linked to a flagellin protein. The present invention is not limited to the order in which bacteria and conjugate vaccines are administered. In some embodiments, the time interval between the first and second vaccinations is one week, two weeks, three weeks, 1 month, 2 months, 3 months, 4 months, 5 months, 6 months, 7 months, 8 months, 9 months, 10 months, 11 months, one year, 1.5 years and two years. Immunization schedules have been scheduled and administered at 1 month intervals, with a priming immunization followed by two sequential booster immunizations.

In some embodiments, the vaccines of the invention are administered with a pharmaceutically acceptable carrier, such that it provides host immunity against an infection.

The term "carrier" denotes an organic or inorganic ingredient, natural or synthetic, with which the active ingredient is combined to facilitate the application without diminishing the immunogenicity of the vaccine. The characteristics of the carrier depend on the nature of the vaccine and the route of administration. Physiologically and pharmaceutically-acceptable carriers include diluents, fillers, salts, buffers, stabilizers, solubilizers, and other materials which are well known in the art. The term "pharmaceutically acceptable" is used to refer to a non-toxic material that is compatible with a biological system such as a cell, cell culture, tissue, or organism.

In practicing immunization protocols for treatment and/or prevention, an immunologically-effective amount of conjugate is administered to a subject. As used herein, the term "immunologically-effective amount" means the total amount of therapeutic agent (e.g., conjugate) or other active component that is sufficient to show an enhanced immune response in the subject. When "immunologically-effective amount" is applied to an individual therapeutic agent administered alone, the term refers to that therapeutic agent alone. When applied to a combination, the term refers to combined amounts of the ingredients that result in the therapeutic effect, whether administered in combination, serially or simultaneously, and regardless of order of administration.

The particular dosage depends upon the age, weight, sex and medical condition of the subject to be treated, as well as on the method of administration. Suitable doses can be readily determined by those of skill in the art.

The conjugate vaccines of the invention can be administered by either single or multiple dosages of an effective amount. In some embodiments, an effective amount of the compositions of the invention can vary from 0.01-5,000 µg/ml per dose. In other embodiments, an effective amount of the composition of the invention can vary from 0.1-500 µg/ml per dose, and in other embodiments, it can vary from 10-300 µg/ml per dose. In one embodiment, the dosage of the

conjugate administered will range from about 10 μg to about 1000 μg. In another embodiment, the amount administered will be between about 20 μg and about 500 μg. In some embodiments, the amount administered will be between about 75 μg and 250 μg. Greater doses may be administered on the basis of body weight. The

5   exact dosage can be determined by routine dose/response protocols known to one of ordinary skill in the art.

In some embodiments, the amount of conjugate that provides an immunologically-effective amount for vaccination against bacterial infection is from about 1 μg or less to about 100 μg or more. In some embodiments, it is from

10   about 2, 3, 4, 5, 6, 7, 8, 9, 10, 15, 20, 25, 30, 35, 40, 45 or 50 μg to about 55, 60, 65, 70, 75, 80, 85, 90, or 95 μg per kg body weight. In a preferred embodiment, the immunologically-effective amount for vaccination against bacterial infection is from 0.01 μg to 10 μg.

The term "subject" as used herein, refers to animals, such as mammals. For

15   example, mammals contemplated include humans, primates, dogs, cats, sheep, cattle, goats, pigs, horses, chickens, mice, rats, rabbits, guinea pigs, and the like. The terms "subject", "patient", and "host" are used interchangeably.

The conjugate vaccine of the present invention may confer resistance to *S.* Enteritidis or *S.* Typhimurium by either passive immunization or active

20   immunization. In one embodiment of passive immunization, the vaccine is provided to a subject (i.e. a human or mammal), and the elicited antisera is recovered and directly provided to a recipient suspected of having an infection caused by *S.* Enteritidis or *S.* Typhimurium.

The ability to label antibodies, or fragments of antibodies, with toxin labels

25   provides an additional method for treating *S.* Enteritidis or *S.* Typhimurium infections when this type of passive immunization is conducted. In this embodiment, antibodies, or fragments of antibodies which are capable of recognizing the *S.* Enteritidis or *S.* Typhimurium antigens are labeled with toxin molecules prior to their administration to the patient. When such a toxin

30   derivatized molecule binds to a *S.* Enteritidis or *S.* Typhimurium cell, the toxin moiety will cause the death of the cell.

In some embodiments, the present invention provides a means for preventing or attenuating infection by *S*. Enteritidis or *S*. Typhimurium, or by organisms which have antigens that can be recognized and bound by antisera to the polysaccharide and/or protein of either the conjugated vaccine or the attenuated bacterial vaccine strains. As used herein, a vaccine is said to prevent or attenuate a disease if its administration to an individual results either in the total or partial attenuation (i.e. suppression) of a symptom or condition of the disease, or in the total or partial immunity of the individual to the disease.

The administration of the vaccine (or the antisera which it elicits) may be for either a "prophylactic" or "therapeutic" purpose. When provided prophylactically, the vaccine is provided in advance of any symptom of *S*. Enteritidis or *S*. Typhimurium infection. The prophylactic administration of the vaccine serves to prevent or attenuate any subsequent infection. When provided therapeutically, the vaccine is provided upon the detection of a symptom of actual infection. The therapeutic administration of the vaccine serves to attenuate any actual infection.

Either the conjugate vaccines (or antisera which it elicits) or the attenuated bacterial vaccine strains of the present invention may, thus, be provided either prior to the onset of infection (so as to prevent or attenuate an anticipated infection) or after the initiation of an actual infection.

The invention also provides a method for inducing an immune response which comprises administering to an individual, suspected of being at risk for infection caused by *S*. Enteritidis or *S*. Typhimurium, an immunologically-effective amount of an antisera elicited from the exposure of a second individual to a conjugate or bacterial vaccine (or combinations thereof) of the invention, such that it provides host immunity to the infection.

The conjugate vaccine of the invention may be administered to warm-blooded mammals of any age. The conjugate vaccines can be administered as a single dose or in a series including one or more boosters. In some embodiments, the immunization schedule would involve a primary series of three immunizations with a spacing of 1-2 months between the doses. In some settings a booster dose could be administered ~ 6-12 months later. For example, an infant can receive

three doses at 6, 10 and 14 weeks of age (schedule for infants in sub-Saharan Africa) or at 2, 4, and 6 months of life (schedule for U.S. infants). U.S. infants might receive a booster at 12-18 months of age. Another target population would be U.S. elderly who would likely receive 2-3 doses spaced 1-2 months apart.

5   In some embodiments, the conjugates can be administered concomitantly with (or in some instances even in combination with) various vaccines either currently being used or in development, whether intended for human or non-human subjects. Examples of vaccines for human subjects and directed to infectious diseases include the combined diphtheria and tetanus toxoids; pertussis whole cell

10   vaccine; acellular pertussis vaccine; inactivated or live intranasal influenza vaccines; 7-valent, 10-valent or 13-valent pneumococcal conjugate vaccines; 23-valent pneumococcal vaccine (relevant to adults, particularly elderly); live measles vaccine; live mumps vaccine; live rubella vaccine; live varicella vaccine; Bacille Calmette-Guerin (BCG) tuberculosis vaccine; hepatitis A vaccine; hepatitis B

15   vaccine; rabies vaccine (e.g., human diploid cell vaccine); inactivated polio vaccine; live oral polio vaccine; bivalent or quadrivalent meningococcal polysaccharide vaccine; monovalnet (group A) or quadrivalent meningococcal conjugate vaccine; yellow fever live virus vaccine; oral or parenteral typhoid vaccines; oral cholera vaccines; Japanese B encephalitis killed virus vaccine;

20   rotavirus vaccine; and other commercially available and experimental vaccines.

Methods of manufacture of a Flagellin Protein derived from *S.* Enteritidis or *S.* Typhimurium

          When generating attenuated vaccines for use as live oral vaccines or for the

25   improved manufacture of components used to make a conjugate vaccine (including, for example, OPS and a flagellin protein), attention to the degree of attenuation must be considered. In regard to large-scale manufacturing, attenuation is particularly important so as to ensure safety in the manufacturing process (including, for example, environmental and occupational health safety).

30   Thus, attenuated *S.* Enteritidis or *S.* Typhimurium strains to be used must be sufficiently and appropriately attenuated to ensure safety for oral administration to

humans (and other mammals at risk of NTS disease) but also for large-scale fermentation of *S*. Enteritidis or *S*. Typhimurium to produce components for making conjugate vaccines.

5   In particular, aspects of the invention are drawn to the large-scale fermentation of *S*. Enteritidis or *S*. Typhimurium strains to derive components for making a conjugate vaccine. In some embodiments, the attenuated strain produces, for example, more flagella than wild-type *S*. Enteritidis or *S*. Typhimurium or exports flagellin protein as monomers rather than as polymerized flagella filaments.

10   In certain aspects of the invention, an attenuated strain having increased expression of flagella compared to a wild-type strain is particularly advantageous from at least a manufacturing perspective. In particular aspects of the invention, an attenuated *S*. Enteritidis or *S*. Typhimurium strain having one or more mutations described herein leading to attenuation and hyperflagellation can be used either for

15   manufacturing as an oral vaccine or for improved, safer and more economical large-scale production of components to make a conjugate vaccine. For example, an attenuated strain of *S*. Enteritidis or *S*. Typhimurium having a mutation in the *guaBA* locus, the *guaB* gene, or the *guaA* gene, and mutation in the *clpP* gene (or *clpPX* locus) produces an attenuated and phenotypically hyperflagellated strain.

20   Methods of purification of a flagellin protein from whole flagella are known in the art or can be readily modified by one of ordinary skill in the art using methods know in the art. For example, by modifying the method of Ibrahim et *al.*, purification of flagella is achieved; below pH 3.0, flagella dissociate into flagellin subunits (Ibrahim *et al. J. Clin. Microbiol.* 1985; 22:1040-4. Further methods for

25   purification include adaptation of the mechanical shearing, and sequential centrifugation steps for purification of flagellin in flagella from bacterial cells. Modern purification methods and *clpP* mutants should markedly increase yield and purity of a flagellin protein used to construct a conjugate vaccine of the invention (see, for example, Ogushi *et al. J. Biol. Chem.* 2001; 276:30521-6; Yoon *et al.*

30   *Infect. Immun.* 2008; 76:1282-8).

In other aspects of the invention, export of a flagellin protein monomer from an attenuated *S*. Enteritidis or *S*. Typhimurium strain is used to derive a

flagellin protein used to construct a conjugate vaccine of the invention. For example, a mutation in the *fliD* gene, *flgL* gene, or *flgK* gene causes export of flagellin monomers into the supernatant. Therefore, in some embodiments, an attenuated *S.* Enteritidis or *S.* Typhimurium strain of the invention having a

5   primary attenuating mutation in either the *guaBA* locus, the *guaB* gene, or the *guaA* gene, may be further engineered to contain an additional mutation in either the *fliD* gene, *flgL* gene, or *flgK* gene to export FliC monomers into the extracellular medium. In some embodiments, such attenuated *S.* Enteritidis or *S.* Typhimurium strain having a primary attenuating mutation further has a mutation in the *clpP*

10   gene (or *clpPX* locus). Such strains will serve as a single source for both safe production of a conjugate vaccine as well as for use as a live vaccine strain.

In a particular embodiment of the invention, *S.* Enteritidis or *S.* Typhimurium containing a *guaBA* mutation and a *fliD* mutation is made and used to derive a flagellin protein in monomeric subunit form to be used to construct a

15   homologous conjugate vaccine of the invention. Mutation of both the *guaBA* and *fliD* gene can be accomplished by a number of methods, including the method of lambda Red-mediated mutagenesis mentioned in previous sections of the invention.

In addition to the attenuated *S.* Enteritidis or *S.* Typhimurium strains

20   described herein for vaccination purposes, and for deriving a flagellin protein used as a component of the conjugate vaccine described herein, these strains can be used to derive OPS that are used as a component of the conjugate vaccine described herein. The invention also encompasses any of the foregoing mutations in any combination that provides for maximum efficacy or manufacturing results (e.g.,

25   any combination of mutations in *guaBA* locus, the *clpPX* locus, the *guaB* gene, *guaA* gene, *clpP* gene, *clpX* gene, *fliD* gene, *flgL* gene, *flgK* gene, or any other mutation described herein which can be made in all possible combinations or variations).

Kits

30   In some embodiments, the invention is directed to kits comprising vaccines of the invention. Such kits can be provided to an administering physician or other health care professional. In some embodiments, the kit is a package which houses

a container which contains the conjugate vaccine composition and instructions for administering the conjugate vaccine composition to a subject. In some embodiments, the kit can also contain one or more other therapeutic agents. The kit can optionally contain one or more diagnostic tools and instructions for use. For example, a vaccine cocktail containing two or more vaccines can be included, or separate pharmaceutical compositions containing different vaccines or therapeutic agents. The kit can also contain separate doses of the conjugate vaccine for serial or sequential administration. The kit can also contain a composition comprising one or more attenuated *Salmonella* strains of the invention. The kit can contain suitable delivery devices, e.g., syringes, inhalation devices, and the like, along with instructions for administrating the therapeutic agents. The kit can optionally contain instructions for storage, reconstitution (if applicable), and administration of any or all therapeutic agents included. The kits can include a plurality of containers reflecting the number of administrations to be given to a subject. If the kit contains a first and second container, then a plurality of these can be present.

While the invention has been described with reference to certain particular examples and embodiments herein, those skilled in the art will appreciate that various examples and embodiments can be combined for the purpose of complying with all relevant patent laws (e.g., methods described in specific examples can be used to describe particular aspects of the invention and its operation even though such are not explicitly set forth in reference thereto).

EXAMPLE 1

CONSTRUCTION of SAFE *S.* Enteritidis and *S.* Typhimurium STRAINS

A key aspect of the invention is the construction of clinically well tolerated attenuated strains of *S.* Enteritidis and *S.* Typhimurium for use as live oral vaccines; for safer, more economical manufacture of purified OPS and flagellin subunit protein to prepare conjugate vaccine for parenteral administration, as well as using these strains in a heterologous mucosal prime/parenteral boost immunization strategy to broaden both the immunogenicity and protective capacity of the conjugate vaccines. We therefore deleted both the *guaBA* and *clpP* genes from both *S.* Enteritidis strain R11 and *S.* Typhimurium strain I77, using a highly

efficient site-directed lambda Red-mediated mutagenesis technique. Deletion regions in the chromosomes of each of the resulting attenuated strains were sequenced to confirm that only the intended genes and DNA sequences had been removed. Having created these basic attenuated candidate vaccine strains, we then

5   sequentially introduced further mutations into *fliD* to secrete FliC monomers, as well as deleting the *fljBA* locus encoding phase 2 flagellin FlgB and the FliC repressor protein FljA from *S*. Typhimurium (*S*. Enteritidis encodes only phase 1 flagella). A list of the attenuated strains now available for purification of OPS and FliC conjugate components is shown in **Table 1.**

TABLE 1. Attenuated NTS strains and expected levels of flagellin production*

Strain	Chromosomal deletions	Expected phenotype
S. Typhimurium		
CVD 1920	*guaBA*	Wildtype FliC and FljB flagella
CVD 1921	*guaBA clpP*	Hyper-expression of FliC and FljB flagella
CVD 1922	*guaBA fliD*	Expression of FliC and FljB **monomers**
CVD 1923	*guaBA clpP fliD*	Hyper-expression of FliC and FljB **monomers**
CVD 1924	*guaBA clpP fljBA*	Hyper-expression of FliC flagella
CVD 1925	*guaBA clpP fliD fljBA*	Hyper-expression of FliC **monomers**
S. Enteritidis		
CVD 1940	*guaBA*	Wildtype FliC expression
CVD 1941	*guaBA clpP*	Hyper-expression of FliC flagella
CVD 1942	*guaBA fliD*	Expression of FliC **monomers**
CVD 1943	*guaBA clpP fliD*	Hyper-expression of FliC **monomers**

* All strains containing the *guaBA* deletion are dependent on guanine supplementation for growth

10

A detailed discussion of the engineering of attenuated *S*. Typhimurium strain CVD 1925 is included here. Since the homologous chromosomal regions for both *S*. Typhimurium and *S*. Enteritidis are nearly identical for *guaBA*, *clpPX*, and

15   *fliD*, primers used for lambda Red-mediated mutagenesis were identical, so mutagenesis of *S*. Typhimurium illustrates the engineering steps taken for generation of mutants for both serovars (with the exception of *fljBA* which is not encoded by *S*. Enteritidis). All primers used for this work are listed in **Table 2**).

20

TABLE 2

Name	Sequence	SEQ ID NO:
P1	GTGTAGGCTGGAGCTGCTTC	9
P4	ATTCCGGGGATCCGTCGACC	10
guaBAF	TGTTTATGCTGCTGATCGAAC	11
guamutR2	**GAAGCAGCTCCAGCCTACAC**GGGCAATATCTCACCTGG	12
guamutF3	**GGTCGACGGATCCCCGGAT**GCCGATAATCCTTCCTGTG	13
guaBAR2	ATAACCTGGACACTTCTGAG	14
guaBAF2	TTCGAAGTGATCACCCCAAC	15
guaBAR3	TATTTGGGCTGAATCGCCAC	16
clpPXF	TAAGCGTCGTGTAGTTGTCG	17
clpmutR	**GAAGCAGCTCCAGCCTACA**CATTACATTTCCGTCTCCTGG	18
clpmutF3	**GGTCGACGGATCCCCGGAAT**TGATGCCCTGGACGCAAGTG	19
clpPR	TAACGTAATCGTCCAGGTGG	20
clpPXF2	AGAAACAGGCTCTGGAGCTG	21
CVOL88	ACGGCGTGTTTACAGGAAAAACGAAAGGGG	22
fljBAF2	TATGACACTTGATCATGTGATG	23
fljBAmutR3	**GAAGCAGCTCCAGCCTACA**CCCAATAAATCGTGTGGCTG	24
fljBAmutF3	**GGTCGACGGATCCCCGGAAT**CGCCTACGGTAATAAAAAATTC	25
fljBAR	TGAGAACTTCAGCAAATCGAC	26
fljBAF3	ACGTCATAAATCGAACAAGTCG	27
fljBAR2	AGCTTCAGCATTGCATCAGC	28
t5FliD	GAATTCtcacgcacacgctgcagg	29

5FliD-rev	GCTAGCacctaatgatgaaattgaagccatgc	30
5FRT-aph	GAATTCGCTAGCGCTGGAGCTGCTT Cgaagttc	31
3FRT-aph	ctcgagTTCCGGGGATCCGTCGACCTG CAGTTC	32
3fliD	GGATCCgctatgaacaagtcctgataacagaggt	33
3FliD-rev	CTCGAGttaacgagactcctggaaagatgctttcggt gaaatctgc	34
g1020	GATTGACTGAGCAGCGCAATACGC TG	35
g1028	GGTGATTTCAGCCTGGATGGAGTCG A	36

* Bold indicates DNA complementary to primers P1 and P4

The *guaBA* locus was deleted from *S.* Typhimurium and *S.* Enteritidis using the lambda Red recombinase system. DNA upstream of *guaB* was amplified using primers guaBAF (SEQ ID NO: 11) and guamutR2 (SEQ ID NO:12) and DNA downstream of *guaA* was amplified using primers guamutF3 (SEQ ID NO:13) and guaBAR2 (SEQ ID NO:14) (**FIG. 2**). The kanamycin resistance cassette from pKD13 was amplified using primers P1 (SEQ ID NO:9) and P4 (SEQ ID NO:10). The 3 PCR products were combined and overlapping PCR was used to generate *guaBA*::Km^R DNA. The Km^R cassette was integrated into the genome by homologous recombination using lambda Red recombinase and then removed using Flp encoded by pCP20 resulting in replacement of *guaBA* with an ~80-bp scar sequence. The deletion was verified by amplification using primers guaBAF2 (SEQ ID NO:15) and guaBAR3 (SEQ ID NO:16) that are outside the deleted region and the PCR product from CVD 1925 was sequenced (SEQ ID NO:37).

For deletion of the *clpP* gene, DNA upstream of *clpP* was amplified using primers clpPXF (SEQ ID NO:17) and clpmutR (SEQ ID NO:18) and DNA downstream of *clpP* was amplified using primers clpmutF3 (SEQ ID NO:19) and clpPR (SEQ ID NO:20) (**FIG. 3**). The kanamycin resistance cassette from pKD13 was amplified using primers P1 (SEQ ID NO:9) and P4 (SEQ ID NO:10). The 3 PCR products were combined and overlapping PCR was used to generate *clpP*::Km^R DNA. The Km^R cassette was integrated into the genome by

homologous recombination using lambda Red recombinase and then removed using Flp encoded by pCP20 resulting in replacement of *clpP* with an ~80-bp scar sequence. The resulting mutant has a *clpP* polar mutation (prevents translation of *clpX*, the second gene in the operon). The deletion was verified by amplification using primers clpPXF2 (SEQ ID NO:21) and CVOL88 (SEQ ID NO:22) that are outside the deleted region and the PCR product from CVD 1925 was sequenced(SEQ ID NO:38).

The *fljBA* locus was deleted from *S.* Typhimurium by amplifying DNA upstream of *hixL* (the upstream site recognized by the recombinase encoded by *hin*) using primers fljBAF2 (SEQ ID NO:23) and fljBAmutR3 (SEQ ID NO:24) and DNA downstream of *fljA* was amplified using primers fljBAmutF3 (SEQ ID NO:25) and fljBAR (SEQ ID NO:26) (**FIG. 4**). The kanamycin resistance cassette from pKD13 was amplified using primers P1 (SEQ ID NO:9) and P4 (SEQ ID NO:10). The 3 PCR products were combined and overlapping PCR was used to generate *fljBA*::Km^R DNA. The Km^R cassette was integrated into the genome by homologous recombination using lambda Red recombinase and then removed using Flp encoded by pCP20 resulting in replacement of *fljBA* with an ~80-bp scar sequence. The deletion was verified by amplification using primers fljBAF3 (SEQ ID NO:27) and fljBAR2 (SEQ ID NO:28) that are outside the deleted region and the PCR product from CVD 1925 was sequenced (SEQ ID NO:39).

For deletion of *fliD* a slightly different approach was taken. DNA upstream of *fliD* was amplified using primers t5fliD (SEQ ID NO:29) and t5fliD-rev (SEQ ID NO:30) and DNA downstream of *fliD* was amplified using primers 3fliD (SEQ ID NO:33) and 3fliD-rev (SEQ ID NO:34) (**FIG. 5**). The kanamycin resistance cassette from pKD13 was amplified using primers 5FRT-aph (SEQ ID NO:31) and 3FRT-aph (SEQ ID NO:32), and the complete Δ*fliD-aph* cassette was assembled using unique restriction enzyme sites engineered within the individual cassettes. As with the previous mutations of CVD 1925, this Δ*fliD-aph* Km^R cassette was integrated into the genome by homologous recombination using lambda Red recombinase and then removed using Flp encoded by pCP20 resulting in replacement of *fliD* with an ~80-bp scar sequence. The deletion was verified by amplification using primers outside the deleted region using primers g1020 (SEQ

ID NO:35) and g1028 (SEQ ID NO:36) and the PCR product from CVD 1925 was sequenced (SEQ ID NO:40).

To ascertain which of these strains might be most useful for purification of FliC, we examined production of flagellin in supernatants using SDS-PAGE gels stained with Coomassie brilliant blue. As shown in **FIG. 6**, introduction of Δ*clpP* significantly improved production of flagella (red arrow; 51.6 kDa) in both *S.* Enteritidis and *S.* Typhimurium. However, further introduction of Δ*fliD* into *S.* Enteritidis Δ*guaBA*Δ*clpP* strains seemed to reduce FliC production. The highest levels of FliC production in attenuated strains of *S.* Typhimurium strains were observed in Δ*guaBA*Δ*clpP*Δ*fliD*Δ*fljBA* strain CVD 1925. As expected, when examined for motility, Δ*guaBA*Δ*clpP* strains appeared to be hyper-motile and Δ*guaBA*Δ*clpP*Δ*fliD* strains hyper-expressing FliC monomers were non-motile. For our first attempt at synthesis of an OPS-FliC conjugate vaccine, we chose to focus on the attenuated *S.* Enteritidis candidate vaccine strain CVD 1941 (Δ*guaBA*Δ*clpP*).

<div align="center">EXAMPLE 2</div>

SYNTHESIS of an OPS-FliC CONJUGATE VACCINE AGAINST *S.* Enteritidis. **Purification of Flagella from CVD 1941.** Several methods were tested for flagellin purification including: 1] an acidic pH2 method used to disaggregate flagella from intact cells at low pH, 2] a mechanical shearing method used to remove whole flagella from intact cells, 3] a heating method used to disaggregate flagella from intact cells, and 4] purification of passively shed flagella from bacterial supernatant. Each method was assessed for purity of the final flagellin prep, yield of protein, and ease of use. Of these, utilization of the commonly used shear method for flagellin production was found to provide the highest yield and purity with the greatest ease of use. Briefly the shear method utilizes a mechanical disruption of flagella on the surface of cells through processing in a Waring blender. Sheared flagella are then separated from large cellular debris particles through centrifugation at 10,000x*g* that will separate debris from intact flagella filaments. The 10,000x*g* supernatant is then subjected to 100,000x*g* centrifugation to pellet high molecular weight large flagella structures, leaving free low-

molecular weight proteins and complexes in the supernatant. The whole flagella obtained from the 100,000x*g* centrifugation are further depleted of contaminating LPS by heating to disaggregate the flagellar filaments into individual proteins, followed by filtration through a 100kDa molecular weight cut-off (MWCO)

5   Amicon ultrafiltration device. Protein purity and integrity were assessed using SDS-PAGE gels stained with Coomassie brilliant blue. LPS contamination was assessed by the Limulus Amebocyte Lysate Assay with chromogenic endpoint analysis. As shown in **FIG. 7**, the resulting preparation was highly enriched for flagellin protein (lane 4). The enriched flagellin polymer preparation was

10 disaggregated into monomers by heat dispersion at 70 degrees C for 15 minutes and passed through a 100KD Molecular Weight Cutoff Amicon Ultrafiltration unit. The resulting flagellin monomer sample (FIG. 7A , lane 3) contained very low levels of LPS, and was judged suitable for conjugation to polysaccharide.

Purification of LPS, and generation of OPS from CVD 1941. For purification of

15 LPS, a method was developed in which a suspension of *Salmonella* was lysed in the presence of nuclease (to degrade bacterial DNA and RNA) by mechanical pressure using a French Press. Lysed cells were further treated with protease to degrade bacterial proteins. LPS was then separated from degraded cellular debris by ethanol precipitation in the presence of excess magnesium. Preparations were

20 further purified from contaminating protein by phenol extraction. The resulting LPS was analyzed on SDS-PAGE gels and visualized by silver stain analysis. As shown in **FIG. 8A**, LPS preparations were determined to be of high purity. Final preparation of core-OPS polysaccharide for use in conjugation reactions involved removal of Lipid A by mild acid treatment at 100°C for 1.5 hours in the presence

25 of 1% acetic acid. Free Lipid A was removed by centrifugation at 100,000x*g* for 5 hours to pellet insoluble Lipid A complexes. The supernatant from the 100,000x*g* centrifugation was assessed by Limulus Amebocyte Lysate assay to be depleted of Lipid A. High molecular weight OPS suitable for conjugation was obtained by size exclusion chromatography (**FIG. 8B**). Polysaccharide concentration in elution

30 fractions was monitored by assay with resorcinol with LPS as a standard. High molecular weight fractions were selected for use in conjugation.

Synthesis of an *S.* Enteritidis OPS-FliC conjugate vaccine. Isolated monomeric flagellin was concentrated using a 10kDa MWCO Amicon Ultrafiltration device, and then directly conjugated in approximately equivalent amounts (gram:gram) with core-OPS polysaccharide that had been derivatized and activated beforehand

5   with CDAP chemistry. 3mg of High Molecular weight OPS (HMW-OPS) in 10mM Borate buffer and 150mM NaCl at pH8.6 was added to 5mg of 100mg/ml CDAP in Acetonitrile. The pH was adjusted to 9.9 with TEA. At 2.5 minutes, 3mg of flagellin monomer protein was added. The reaction was incubated at 25 degrees C for 1.5 hours, 18 hours at 4 degrees C, and then -20 degrees C for 4 days. The

10   reaction was then quenched with 2M glycine. Initial assessment of conjugation was accomplished by analytical SEC-HPLC and monitoring for protein elution by UV spectroscopy absorbance at 280nm.   Evidence of conjugation was seen by broadening and flattening of the defined peaks in the elution profile, with broad peaks between 6 and 9 minutes which were not observed in the retention peaks

15   from the unconjugated material (data not shown). The resulting conjugate was also analyzed by SDS-PAGE gels stained with Coomassie brilliant blue for protein (FIG 9A), Emerald Green staining for polysaccharide (**FIG. 9B**), as well as transferred to PVDF membranes and analyzed by Western blot with a monoclonal antibody (15D8, Bioveris) for flagellin (**FIG. 9C**). As shown in **FIG 9A and B,**

20   **lane 4**, evidence of conjugation between OPS and FliC is clearly seen in the high molecular weight species observed above the protein band corresponding to unreacted FliC, that double stains positive for both protein and polysaccharide; further evidence of successful conjugation is indicated by the fact that these higher molecular weight species are recognized by an antibody specific for flagellin, **FIG.**

25   **9C, lane 2**. As controls, purified LPS samples separated in **FIG. 9A, lane 1** did not stain with the Coomassie protein stain, and strongly stained for polysaccharide by Emerald Green stain (**FIG. 9B, lane 1**) with the expected banding pattern characteristic of LPS. Purified flagellin samples separated in **FIG. 9A, lane 3** strongly stained with Coomasie dye, but not with Emerald Green. The flagellin

30   protein was also strongly recognized by anti-flagellin antibody (**FIG. 9C, lane 1**). Flagellin-High Molecular Weight OPS conjugates were purified from un-reacted Flagellin and OPS components by size fractionation with the use of size exclusion

chromatography (**FIG. 10A**). High molecular weight fractions that eluted prior to unreacted flagellin (**FIG. 10A, lanes 8-11**) were pooled and deemed suitable for use in vaccination against the homologous NTS strains that they were derived from.

5   EXAMPLE 3

Purification of FliC monomers from *Salmonella* mutants lacking *fliD*. Initial purification efforts focused on the removal of contaminating LPS from flagellin preparations recovered from the bacterial supernatants, utilizing sequential ion-exchange column chromatography steps. For the ion exchange purifications, the 10 sample was held at a pH below the isoelectric point of flagellin, but above that of LPS, thus causing the two molecules to have overall net opposite charges since flagellin will have converted to a net positive charge under these conditions, while LPS will maintain a net negative charge. Endotoxin content of the purified material was assayed using a Limulus Amebocyte lysate (LAL) assay. SDS-PAGE 15 analysis indicated that the supernatant was effectively concentrated, and flagellin was bound/eluted as expected through the ion-exchange material. Using this method, endotoxin contamination was reduced by ~90%.

While there have been shown and described what are presently believed to be the preferred embodiments of the present invention, those skilled in the art will 20 realize that other and further embodiments can be made without departing from the spirit and scope of the invention described in this application, and this application includes all such modifications that are within the intended scope of the claims set forth herein. All patents and publications mentioned and/or cited herein are incorporated by reference to the same extent as if each individual publication was 25 specifically and individually indicated as having been incorporated by reference in its entirety.

<u>WHAT IS CLAIMED IS</u>:

1. A method of inducing an immune response, comprising administering to a subject in need thereof an immunologically-effective amount of a *Salmonella enterica* serovar conjugate vaccine comprising an O polysaccharide (OPS) covalently linked to a flagellin protein or a fragment or a derivative thereof, wherein the serovar is selected from the group consisting of *S*. Typhimurium and *S*. Enteritidis.

2. The method of claim 1, wherein the flagellin protein is a Phase 1 flagella protein.

3. The method of claim 1, wherein the serovar has at least one attenuating mutation selected from group consisting of an attenuating mutation in the *guaBA* locus and the *clpPX* locus.

4. The method of claim 1, wherein the conjugate vaccine is administered parenterally.

5. The method of claim 4, wherein prior to administering the conjugate vaccine, the subject is administered an attenuated strain of the serovar.

6. The method of claim 5, wherein said strain is orally administered to the subject.

7. The method of claim 6, wherein said serovar has at least one attenuating mutation selected from group consisting of an attenuating mutation in the *guaBA* locus and the *clpPX* locus.

8. The method of claim 7, wherein said subject is a human.

9. The method of claim 2, wherein said effective amount is between about 0.01 μg and 10 μg.

10. The method of claim 9, wherein said Phase 1 flagella protein is covalently linked to said OPS either directly or using a linker.

11. The method of claim 10, wherein said linker is selected from the group consisting of 1-cyano-4-dimethylaminopyridinium tetrafluoroborate,

adipic acid dihydrazide, ε-aminohexanoic acid, chlorohexanol dimethyl acetal, D-glucuronolactone and p-nitrophenylethyl amine.

12. The method of claim 11, wherein said linker is 1-cyano-4-dimethylaminopyridinium tetrafluoroborate .

13. The method of claim 8, wherein said conjugate vaccine is combined with a pharmaceutically acceptable carrier in a pharmaceutical composition.

14. A *Salmonella enterica* serovar conjugate vaccine comprising an O polysaccharide (OPS) covalently linked to a flagellin protein or a fragment or a derivative thereof, wherein the serovar is selected from the group consisting of *S*. Typhimurium and *S*. Enteritidis.

15. The vaccine of claim 14, wherein the flagellin protein is a Phase 1 flagella protein.

16. The vaccine of claim 15, wherein the serovar has at least one attenuating mutation selected from group consisting of an attenuating mutation in the *guaBA* locus and the *clpPX* locus.

17. A *Salmonella enterica* serovar strain, wherein said strain has at least one attenuating mutation selected from group consisting of an attenuating mutation in the *guaBA* locus and the *clpPX* locus and said serovar is selected from the group consisting of *S*. Typhimurium (Group B) and *S*. Enteritidis (Group D).

18. The *Salmonella* serovar strain of claim 17, wherein said strain has an attenuating mutation in said *guaBA* locus.

19. The *Salmonella* serovar strain of claim 17, wherein said strain has an attenuating mutation in said *clpPX* locus.

20. The *Salmonella* serovar strain of claim 17, wherein said attenuating mutation is an attenuating mutation that reduces the level of expression of said loci , or blocks expression of said loci.

21. The *Salmonella* serovar strain of claim 17, wherein said attenuating mutation is an attenuating mutation that reduces the activity of a polypeptide encoded by said loci, or inactivates a polypeptide encoded by said loci.

22. The *Salmonella* serovar strain of claim 17, wherein said strain overexpresses Phase 1 flagella protein.

FIG. 1

FIG. 2

FIG. 3

FIG. 4

FIG. 5

FIG. 6

FIG. 7

A.

89KD

36KD

B.

FIG. 8

FIG. 9

FIG. 10